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Abstract Friedreich’s ataxia (FRDA), the most common inherited ataxia, is caused by recessive
mutations that reduce the levels of frataxin (FXN), a mitochondrial iron binding protein. We
developed an inducible mouse model of Fxn deficiency that enabled us to control the onset and
progression of disease phenotypes by the modulation of Fxn levels. Systemic knockdown of Fxn in
adult mice led to multiple phenotypes paralleling those observed in human patients across multiple
organ systems. By reversing knockdown after clinical features appear, we were able to determine
to what extent observed phenotypes represent reversible cellular dysfunction. Remarkably, upon
restoration of near wild-type FXN levels, we observed significant recovery of function, associated
pathology and transcriptomic dysregulation even after substantial motor dysfunction and
pathology were observed. This model will be of broad utility in therapeutic development and in
refining our understanding of the relative contribution of reversible cellular dysfunction at different
stages in disease.
DOI: https://doi.org/10.7554/eLife.30054.001
Introduction
A guanine-adenine-adenine (GAA) trinucleotide repeat expansion within the first intron of the fra-
taxin (Fxn) gene in the chromosome 9 is the major cause of Friedreich’s ataxia (FRDA), the most
commonly inherited ataxia (Chamberlain et al., 1988; Campuzano et al., 1996). Due to recessive
inheritance of this GAA repeat expansion, patients have a marked deficiency of Fxn mRNA and pro-
tein levels caused by reduced Fxn gene transcription (Campuzano et al., 1996; Campuzano et al.,
1997). Indeed, the GAA expansion size has been shown to correlate with residual Fxn levels, earlier
onset, and increased severity of disease (Filla et al., 1996; Montermini et al., 1997). The prevalence
of heterozygous carriers of the GAA expansion is between 1:60 and 1:110 in European populations,
and the heterozygous carriers of a Fxn mutation are not clinically affected (Andermann et al., 1976;
Harding, 1981).
FRDA is an early-onset neurodegenerative disease that progressively impairs motor function,
leading to ataxic gait, cardiac abnormalities, and other medical co-morbidities, ultimately resulting
in early mortality (median age of death, 35 years) (Koeppen and Mazurkiewicz, 2013; Koep-
pen, 2011). However, identification of the causal gene led to identification of a significant number
of patients with late onset, tend to have slower progression with less severe phenotype and are
associated with smaller GAA expansions (Bhidayasiri et al., 2005). This shorter expansion enables
residual Fxn expression (Li et al., 2015), thus modifying the classical FRDA phenotype, consistent
with other data indicating that Fxn deficiency is directly related to the FRDA phenotype
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(Seibler et al., 2005). Extra-neurologic symptoms including metabolic dysfunction and insulin intol-
erance are observed in the majority and frank type I diabetes is observed in approximately 15% of
patients, the severity of which is related to increasing repeat length (Martinez et al., 2017;
Galea et al., 2016; Coppola et al., 2009). The mechanisms by which Fxn reduction leads to clinical
symptoms and signs remain to be elucidated, but molecular and cellular dysfunction mediated by a
critical reduction in Fxn levels plays a central role (Pandolfo, 2002).
FXN is a nuclear-encoded mitochondrial protein involved in the biogenesis of iron-sulphur clus-
ters, which are important for the function of the mitochondrial respiratory chain activity
(Abraha˜o et al., 2015; Tanaka et al., 1996). Studies in mouse have shown that Fxn plays an impor-
tant role during embryonic development, as homozygous frataxin knockout mice display embryonic
lethality (Cosse´e et al., 2000), consistent with FXN’s evolutionary conservation from yeast to human
(Campuzano et al., 1996; Campuzano et al., 1997). Over the past several years, multiple mouse
models of frataxin deficiency, including a knock-in knockout model (Miranda et al., 2002), repeat
expansion knock-in model (Miranda et al., 2002), transgenic mice containing the entire Fxn gene
within a human yeast artificial chromosome, YG8R and YG22R (Al-Mahdawi et al., 2004; Al-
Mahdawi et al., 2006), as well as a conditional Fxn knockout mouse, including the cardiac-specific
(Puccio et al., 2001) and a neuron specific model (Puccio et al., 2001) have been generated. These
existing transgenic and heterozygous knockout FRDA animal models are either mildly symptomatic
or restricted in their ability to recapitulate the spatial and temporal aspects of systemic FRDA pathol-
ogy when they are engineered as tissue-specific conditional knockouts (Miranda et al., 2002; Al-
Mahdawi et al., 2004; Al-Mahdawi et al., 2006; Puccio et al., 2001; Simon et al., 2004;
Perdomini et al., 2013). Despite advances made towards elucidating FRDA pathogenesis, many
questions remain due to the need for mouse models better recapitulating key disease features to
understand frataxin protein function, disease pathogenesis, and to test therapeutic agents.
In this regard, one crucial question facing therapeutic development and clinical trials in FRDA is
the reversibility of symptoms. The natural history of the disorder has been well described
(Metz et al., 2013; Nakashima et al., 2014), it is not known how clinical features such as significant
motor disability relate to reversible processes (e.g. underlying neuronal dysfunction) or reflect irre-
versible cell death. It is often assumed that clinically significant ataxia and motor dysfunction reflects
neurodegeneration, although this may not be the case. This issue, while critically important for thera-
peutic development, is difficult to address in patients, but we reasoned that we could begin to
address this question in an appropriate mouse model.
Here we report an inducible mouse model for FRDA, the FRDAkd mouse, that permits reversible,
and yet substantial frataxin knockdown, allowing detailed studies of the temporal progression, or
recovery following restoration of frataxin expression - the latter permitting exploration of disease
reversal given optimal treatment (normalization of Fxn levels). We observe that Fxn knockdown leads
to behavioral, physiological, pathological, and molecular deficits in FRDAkd mice paralleling those
observed in patients, including severe ataxia, cardiac conduction defects and increased left ventricu-
lar wall thickness, iron deposition, mitochondrial abnormalities, low aconitase activity, and degenera-
tion of dorsal root ganglia and retina, as well as early mortality. We identify a signature of molecular
pathway dysfunction via genome-wide transcriptome analyses, and show reversal of this molecular
phenotype and as well as behavioral and pathological measures, even in the setting of significant
disability due to motor dysfunction in FRDAkd animals.
Results
RNA interference based in vivo frataxin knockdown and rescue
To investigate the neurological and cardiac effects linked to reduced FXN levels and to create a
model for testing new therapies in vivo, we sought to generate mice that develop titratable clinical
and pathological features of FRDA. We employed recombinase-mediated cassette exchange for
genomic integration of a single copy shRNA transgene (doxycycline-inducible) that can mediate fra-
taxin silencing temporally under the control of the H1 promoter via its insertion in a defined genomic
locus that is widely expressed (rosa26 ) (Seibler et al., 2007). This allowed us to circumvent the
lethal effect of organism-wide knockout, while permitting significant frataxin reduction in all tissues.
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Figure 1. Efficient temporal in vivo frataxin knockdown and rescue. (a) Schematic representation of the inducible expression vector system delivering
shRNA against frataxin. The vector contains an shRNA sequence against the frataxin (Fxn) gene regulated by the H1 promoter with tet-operator
sequences (tetO) and tet repressor (tetR) under the control of the CAGGS promoter. Transcription of the Fxn shRNA is blocked in cells expressing tetR.
Upon induction by doxycycline (dox), tetR is removed from the tetO sequences inserted into the promoter, allowing transcription of shRNA against Fxn.
Figure 1 continued on next page
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Depending on the dose of the inductor doxycycline (dox), temporal Fxn knockdown was achieved to
control the onset and progression of the disease (Figure 1a).
Six different shRNA sequences were screened in vitro to obtain a highly efficient shRNA targeting
the mature coding sequence of frataxin (Figure 1b and Figure 1—figure supplement 1). To exam-
ine off-target effects, we utilized the shRNA sequence (GGATGGCGTGCTCACCATTAA) to identify
potential putative off-target effects in the mouse genome using BLASTN, finding that the second
closest match after Fxn had only 16 out of 21 bases matching. We observe that Fxn is the earliest
gene product reduced at the transcriptomic level, and does not alter the expression levels of other
potential targets (9 genes with 13–16 nucleotide matches; Figure 1—figure supplement 2), consis-
tent with the shRNA’s specificity for Fxn.
Transgenic animals (FRDAkd) containing a single copy of this efficient shRNA transgene
(Figure 1b) were generated and characterized. First, to test Fxn knockdown efficiency, we explored
the response to dox at varying escalating doses in drinking water. At the higher doses, we observed
mortality as early as two weeks and a 100% mortality rate by five to six weeks, not permitting
extended time series analyses ( Materials and methods). We found that the combination of 2 mg/ml
in drinking water coupled with 5 or 10 mg/kg intraperitoneal injection of dox twice per week led to
efficient Fxn knockdown within two weeks post treatment initiation, while avoiding a high early mor-
tality rate (Materials and methods). Hence, for all subsequent experiments we utilized this regimen
to model the chronicity of this disorder in patients by balancing the gradual appearance of clinical
signs and decline in function, while limiting early demise (Figure 1c).
To determine the effect of Fxn deficiency in adult mice after a period of normal development
(similar to a later onset phenotype in humans), which would allow establishment of stable baselines,
and to obtain relatively homogeneous data from behavioral tests (Crawley, 2007), we initiated dox
at three months. Following 20 weeks with (Tg +) or without (Tg -) doxycycline administration
(Figure 1c; Materials and methods), we observed highly efficient silencing of Fxn, reaching greater
than 90% knockdown across multiple CNS and non-CNS tissues (p<0.05, two-way ANOVA;
Figure 1d,e). Using this regimen, time series western blot analyses of 80 independent animals (wild-
type with dox (Wt +) N = 24; transgenic with dox (Tg +) N = 24; transgenic without dox (Tg -)
N = 24; transgenic with dox removal (Rescue Tg ±) N = 8, at weeks 0, 3, 8, 12, 16, and 20) confirmed
efficient silencing as early as three weeks, and efficient rescue, as evidenced by normal frataxin lev-
els, post eight weeks dox removal (p<0.05, two-way ANOVA; Figure 1f,g). Together, the results
indicate that FRDAkd mice treated with dox are effectively FXN depleted in a temporal fashion and
that Fxn expression can be reversed efficiently by dox removal, making it suitable for studying path-
ological and clinical phenotypes associated with FRDA.
Figure 1 continued
shRNA expression leads to RNAi-mediated knockdown of the Fxn gene. (b) Predicted minimum free energy secondary structure of expressed shRNA
targeting the Fxn is shown with the sequence (sense strand) and its complement sequence (antisense strand) in the duplex form along with hairpin
loop. (c) Timeline for doxycycline treatment of mice with a double IP injection (5 and 10 mg/kg) of dox per week and in drinking water (2 mg/ml). IP
injections and dox in water were withdrawn for rescue animals. Arrow signs indicated different time intervals considered for downstream analyses. (d)
Transgenic mice without (Tg -) or with (Tg +) doxycycline treatment (see c) for 20 weeks were analyzed by Western blot for protein levels of FXN in
various organs. (e) For quantification, FXN values were normalized to the level of b-tubulin in each lane. (f) Time series FXN knockdown and rescue in
liver. Wild-type mice with (Wt +), transgenic mice with (Tg +) and without (Tg -) dox, and transgenic mice with (Tg ±) dox removal (rescue) samples were
analyzed for weeks 0,3,8,12,16, and 20. Rescue animals (Tg ±) were given dox for 12 weeks and doxycycline was withdrawn for additional 4 and 8 weeks.
(g) For quantification, FXN values were normalized to the level of b-tubulin in each lane. N = 4 animals per group, *p<0.01; two-way ANOVA test; n.s.,
not significant. Error bars represent mean ±SEM for panels e and g.
DOI: https://doi.org/10.7554/eLife.30054.002
The following source data and figure supplements are available for figure 1:
Source data 1. This spreadsheet contains the Western blot quantification data after frataxin knockdown in various organs and time points in FRDAkd
and control animals which was used to generate the bar plots shown in Figure 1e and g.
DOI: https://doi.org/10.7554/eLife.30054.005
Figure supplement 1. In vitro knockdown validation of Fxn-specific shRNAs.
DOI: https://doi.org/10.7554/eLife.30054.003
Figure supplement 2. Validation of shRNA off-target effects.
DOI: https://doi.org/10.7554/eLife.30054.004
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Frataxin knockdown mice exhibit neurological deficits
The major neurologic symptom in FRDA is ataxia, which, in conjunction with other neurological defi-
cits including axonal neuropathy and dorsal root ganglion loss, contributes to the gait disorder and
neurological disability (Koeppen and Mazurkiewicz, 2013; Koeppen, 2011). So, we first deter-
mined whether Fxn knockdown impacted the behavior of Tg and Wt mice with (+) or without (-) dox,
or with dox followed by its removal (±; the ‘rescue’ condition), leading to a total of five groups sub-
jected to a battery of motor behavioral tasks (each group N = 15–30; total mice = 108;
Materials and methods) (Figure 2a–g). Wt - and Wt + control groups were included to access base-
line and to have a control for any potential dox effect on behavior; Tg - and Tg + transgenic groups
were compared to examine the effect of genotype and Fxn knockdown on behavior; The Tg ± group
was included to study the effect of FXN restoration after knockdown (rescue). We observed signifi-
cant weight loss and reduced survival ratio (<90%) at 25 weeks with dox treatment in Fxn knock-
down animals (Tg +) compared to other control groups (p<0.05, two-way ANOVA; Figure 2a,b). Tg
+ mice exhibited a shorter distance travelled at both 12 and 24 weeks in comparison to control ani-
mals, consistent with decreased locomotor activity (p<0.05, two-way ANOVA; Figure 2c). Next, we
assessed gait ataxia (Koeppen, 2011) using paw print analysis (Dellon and Dellon, 1991)
(Materials and methods). The Fxn knockdown mice (Tg +) displayed reduced hind and front limb
stride length when compared with Tg-, as well as the Wt control + at 12 and 24 weeks, suggesting
ataxic gait (p<0.05, two-way ANOVA; Figure 2d,e and Figure 2—figure supplement 1). Grip
strength testing also showed that Tg + animals displayed defects in their forelimb muscular strength
at 12 and 24 weeks when compared with other groups (p<0.05, two-way ANOVA; Figure 2f). Finally,
motor coordination and balance were evaluated using the Rotarod test. Whereas no significant dif-
ference in time spent on the rod before falling off was seen between Wt + or Wt - or Tg - and Tg ±
mice after 12 weeks post dox removal (rescue), chronically treated mice (Tg +mice) from 12 weeks
onward fell significantly faster, indicative of motor impairments (p<0.05, two-way ANOVA;
Figure 2g). These observations suggest that the knockdown of Fxn in mice causes motor deficits
indicative of ataxia similar to FRDA patients (Koeppen, 2011), and demonstrates the necessity of
normal levels of Fxn expression in adults for proper neurological function.
Frataxin knockdown leads to cardiomyopathy
Cardiac dysfunction is the most common cause of mortality in FRDA (Tsou et al., 2011;
Smyth, 2005). To examine impaired cardiac function in FRDAkd knockdown animals, we employed
electrocardiogram (ECG) and echocardiogram analyses to measure electrical activity and monitor
cardiac dimensions. The ECG of Tg + mice displayed a significant increase in QT interval duration
when compared to the other control/comparison groups at both 12 and 24 weeks post dox treat-
ment, suggesting abnormal heart rate and rhythm (arrhythmia) (Surawicz and Knoebel, 1984)
(Materials and methods; p<0.05, two-way ANOVA; Figure 3a–b,e). However, rescue animals (Tg ±)
12 weeks after dox removal showed a normal ECG, demonstrating that by restoring FXN levels, the
prolonged QT interval can recover (p<0.05, two-way ANOVA; Figure 3b,e). We also observed that
the Tg +animals at week 24 displayed absence of P-waves, suggesting an atrial conduction abnor-
mality (German et al., 2016) (Figure 3c), not observed in the rescued animals. Similar cardiac abnor-
malities have been variably observed in FRDA patients (Dutka et al., 1999).
Progressive hypertrophic cardiomyopathy (thickening of ventricular walls) related to the severity
of frataxin deficiency (Dutka et al., 1999; Isnard et al., 1997; Du¨rr et al., 1996) is frequently
observed in FRDA patients (Tsou et al., 2011). To confirm structural cardiac abnormalities, echocar-
diogram analyses were performed, focusing on left ventricular function. At 12 weeks there was a
non-significant trend towards increasing ventricular wall thickness. However, by 24 weeks, dox
treated transgenic animals (Tg +) exhibited ventricular and posterior wall thickening, suggesting
hypertrophic cardiomyopathy when compared to other control groups (p<0.05, two-way ANOVA;
Figure 3d,f,g). Together, these observations indicate that the transgenic mice exhibit progressive
cardiomyopathy due to reduced level of Fxn, supporting the utilization of Tg + mice for examining
the molecular mechanisms downstream of Fxn deficiency responsible for cardiac defects.
Chandran et al. eLife 2017;6:e30054. DOI: https://doi.org/10.7554/eLife.30054 5 of 41
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Figure 2. Neurological deficits due to frataxin knockdown. Body weight, survival, open field, gait analysis, grip strength and Rotarod in five groups of
animals; wild-type mice with dox (Wt +, n = 16 (WK 0), n = 16 (WK 12), n = 16 (WK 24)) and without dox (Wt -, n = 16 (WK 0), n = 16 (WK 12), n = 16 (WK
24)), transgenic mice with dox (Tg +, n = 30 (WK 0), n = 21 (WK 12), n = 15 (WK 24)) and without dox (Tg -, n = 16 (WK 0), n = 15 (WK 12), n = 15 (WK
24)), and transgenic mice with dox removal (Tg ± Rescue, n = 30 (WK 0), n = 21 (WK 12), n = 20 (WK 24)). (a) Body weight from before 6 weeks and upto
Figure 2 continued on next page
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Cardiac pathology observed with frataxin knockdown
We next explored the pathological consequences of FRDA knockdown in FRDAkd mice. In FRDA
patients, reduced frataxin induces severe myocardial remodeling, including cardiomyocyte iron accu-
mulation, myocardial fibrosis and myofiber disarray (Koeppen, 2011). Indeed, we observed substan-
tially increased myocardial iron in Tg + mice, as evidenced by increased ferric iron staining
(Figure 4a and Figure 4—figure supplement 1) and the increased expression of iron metabolic pro-
teins, ferritin and ferroportin, at 20 weeks (Figure 4b and Figure 4—figure supplement 1). Cardiac
fibrosis is commonly found in association with cardiac hypertrophy and failure (Conrad et al., 1995).
Histological analysis by Masson’s trichrome staining revealed excessive collagen deposition in Tg +
mice hearts at 20 weeks when compared to other control groups, suggesting cardiac fibrosis
(Figure 4c). Further examination of cardiomyocyte ultrastructure by electron microscopy in control
mouse (Wt +) heart demonstrates normally shaped mitochondria tightly packed between rows of
sarcomeres (Figure 4d). In contrast, Tg + mice demonstrate severe disorganization, displaying disor-
dered and irregular sarcomeres with enlarged mitochondria at 20 weeks (Figure 4d). In a minority of
cases, but never in controls, we observed mitochondria with disorganized cristae and vacuoles in Tg
+ mouse heart at 20 weeks, suggesting mitochondrial degeneration (Figure 4e). Next, by examining
aconitase, an Fe-S containing enzyme whose activity is reduced in FRDA patients (Bradley et al.,
2000; Ro¨tig et al., 1997), activities in Tg + and other control groups, we observed decreased aconi-
tase activity in the Tg + mouse heart at 20 weeks. Together these observations suggest that the
knockdown of Fxn in mice causes cardiac pathology similar to that observed in patients
(Smyth, 2005).
Frataxin knockdown causes neuronal degeneration
In FRDA patients and mice with Fxn conditional knockout, a cell population that is seriously affected
by frataxin reduction is the large sensory neurons of dorsal root ganglia (DRG), which results in their
degeneration (Koeppen, 2011). As in heart tissue, lack of Fxn also induces mitochondrial dysfunc-
tion in the DRG (Ro¨tig et al., 1997). Thus, we assessed whether mitochondrial abnormalities are
observed in Tg + mice DRG neurons by electron microscopy (Materials and methods). As antici-
pated, no mitochondrial abnormalities were detected in DRG neurons in the control groups, but a
significant increase in condensed mitochondria were detected in DRG neurons of Tg + mice at 20
weeks (p<0.05, two-way ANOVA; Figure 5), but not in Tg - or Wt + mice. In most case, we observed
empty vesicles associated with condensed mitochondria in DRG neurons of Tg + animals, but not in
other control groups, suggesting neuronal degeneration, similar to what is observed in FRDA
Figure 2 continued
34 weeks after dox treatment. (b) Survival was significantly diminished in dox treated Tg + animals, no mortality was observed after dox withdrawal (Tg
± Rescue). (c) Open field test showing significant decline in total distance traveled by the dox treatment transgenic animals (Tg +) at 12 and 24 weeks
when compared across all other groups. After dox withdrawal, there were no differences between the rescue group (Tg ± Rescue) and the three control
groups at week 24. (d) Gait footprint analysis of all five groups of mice at 0, 12, and 24 weeks was evaluated for stride length. Dox treated transgenic
(Tg +) animals revealed abnormalities in walking patterns displaying significantly reduced stride length; however, the rescue group (Tg ± Rescue)
displayed normal stride length when compared to other groups. (e) Representative walking footprint patterns. (f) Grip-strength test, dox treated
transgenic (Tg +) mice had reduced forelimb grip strength at 12 and 24 weeks when compared across all other groups. After dox withdrawal, there
were no significant differences between the rescue group (Tg ± Rescue) and the three control groups at week 24. (g) Rotarod test in mice upto 34
weeks after dox treatment. Dox treated transgenic (Tg +) animals stayed less time on the Rotarod than the control groups, although after dox
withdrawal, there was no significant difference between the rescue group (Tg ± Rescue) and the three control groups. Values between all five groups
are shown as mean ±SME. Two-way ANOVA test *p0.001; n.s., not significant.
DOI: https://doi.org/10.7554/eLife.30054.006
The following source data and figure supplements are available for figure 2:
Source data 1. This spreadsheet contains the raw data which was used to generate the graphs shown in Figure 2 after frataxin knockdown during vari-
ous behavioral tests in FRDAkd and control animals.
DOI: https://doi.org/10.7554/eLife.30054.009
Figure supplement 1. Gait analysis measurements reveals decreased stride length in Fxn knockdown animals.
DOI: https://doi.org/10.7554/eLife.30054.007
Figure supplement 2. Behavioral changes at twelve weeks in FRDAkd mice.
DOI: https://doi.org/10.7554/eLife.30054.008
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Figure 3. Frataxin knockdown mice exhibit signs of cardiomyopathy. (a) Representative traces of ECG recording in a wild-type and transgenic animal
after dox treatment for 20 weeks, showing long QT intervals in Tg + animal. (b) ECG recording of a same dox treated transgenic (Tg +) animal at 12
and after dox withdrawal for additional 12 weeks (Tg ± Rescue), showing normal QT interval. (c) ECG recording of the same dox treated transgenic (Tg
+) animal at 12 and 24 weeks, showing absence of P-wave only at 24 weeks. (d) Representative echocardiograms from the left ventricle of a wild-type
and transgenic mouse at 24 weeks after dox treatment. (e–f) Quantification of observed QT interval (e), ventricular septal wall thickness (f) and posterior
wall thickness (g) are shown for weeks 12 and 24. N = 6–8 animals per group, *=p < 0.05; Student’s t test. Error bars represent mean ±SEM.
DOI: https://doi.org/10.7554/eLife.30054.010
The following source data is available for figure 3:
Source data 1. This spreadsheet contains the electrocardiogram and echocardiogram quantification data after frataxin knockdown during week 12 and
24 in FRDAkd and control animals which was used to generate the bar plots shown in Figure 3e–g.
DOI: https://doi.org/10.7554/eLife.30054.011
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patients (Koeppen, 2011) (p<0.05, two-way ANOVA; Materials and methods; Figure 5b,c). Nile Red
staining in the DRG neurons of Tg + animals did not display elevated levels of lipid droplets, sug-
gesting further evaluation is needed to identify the composition of these electron-light vesicles (Fig-
ure 5—figure supplement 1). Previous results in human post-mortem spinal cords of FRDA patients
showed a decrease in axon size and myelin fibers (Koeppen and Mazurkiewicz, 2013). By analyzing
more than 2000 axons per group in the lumbar spinal cord cross-section of high-resolution electron
micrographs, we observed significant reduction in axonal size and myelin sheath thickness in the spi-
nal cord samples of Tg + mice when compared to other control groups at 20 weeks (p<0.05, two-
way ANOVA; Figure 6a–c). In the cerebellum, the number of Purkinje cells and the cerebellar granu-
lar and molecular layers were not altered due to Fxn knockdown at 20 weeks (Figure 6—figure sup-
plement 1).
Next we explored the visual system, because various visual field defects have been
reported in patients, suggesting that photoreceptors and the retinal pigment epithelium (RPE) may
be affected (Seyer et al., 2013; Fortuna et al., 2009). By electron microscopic examination of the
photoreceptors in the retina, which are specialized neurons capable of phototransduction, we
observed disruption in Tg + mice at 20 weeks (Materials and methods; Figure 6d). Previous work
has shown that the disruption of photoreceptors is related to visual impairment (Saxena et al.,
2014). Similarly, we also found a significant increase in degenerating RPE cells with vacuoles in Tg +
mice, which is involved in light absorption and maintenance of visual function (Figure 6e). Together,
these results suggest that Fxn knockdown in the CNS of adult mice results in degeneration of retinal
neurons.
The Pdk1/Mef2 pathway and reactive oxygen species in FRDAkd mice
Recently, Pdk1/Mef2 pathway activation has been associated with iron toxicity due to FXN loss in
the neonatal mouse brain and fly (Chen et al., 2016a; Chen et al., 2016b). To examine this in the
FRDAkd model, we performed Western blot analyses to evaluate the phosphorylated levels of PDK
and performed RT-PCR analyses to measure the top five candidate target genes of Mef2 observed
in Chen et al. (Chen et al., 2016b) (Figure 6—figure supplement 2). We measured pPDK levels in
brain, muscle, heart, and liver samples after chronic adult Fxn knockdown, but did not observe
changes in the phosphorylation of S241 in the PDK1 activation loop, which is required for its activity
(Figure 6—figure supplement 2). Next, we analyzed the mRNA levels of the top five candidate tar-
get genes of Mef2 (Sgca, Hrc, Nr4a1, Myom1, and Tcap) in cerebellum and heart after Fxn knock-
down (Chen et al., 2016b). In two independent experiments, each utilizing four biological
replicates, we found that Sgca (one of five genes tested) was significantly over-expressed after Fxn
knockdown in the cerebellum. In the heart, we found Nr4a1 was significantly over-expressed, while
two of the other Mef2c targets, Hrc and Tcap, were significantly down-regulated after Fxn knock-
down. These results suggest that the Pdk1/Mef2 pathway is not consistently or universally activated
in mice with adult FRDAkd following iron accumulation and also suggest tissue-specific pathway acti-
vation due to Fxn knockdown (Figure 6—figure supplement 2).
There is debate as to whether the pathogenesis of several neurodegenerative diseases, including
FRDA, may involve reactive oxygen species (ROS) associated with mitochondrial dysfunction
(Seznec et al., 2005). Indeed, in FRDA the evidence for elevation of ROS in disease pathogenesis is
quite variable (Chen et al., 2016a; Chen et al., 2016b; Seznec et al., 2005; Tamarit et al., 2016;
Schulz et al., 2000; Shidara and Hollenbeck, 2010). To address this in our adult onset model, we
first measured the levels of two markers of oxidative stress, 3-nitrotyrosine (3NT) and 4-hydroxy-2-
nonenal (4-HNE), on brain, liver, and muscle samples from the Wt + and Tg + mice at 12 and 20
weeks, and did not observe any changes in these markers. Next, we utilized the Oxyblot protein oxi-
dation detection kit to detect the carbonyl groups introduced into proteins by oxidative stress, and
again found no evidence for increases in levels of 2,4-dinitrophenylhydrazone (DNP-hydrazone).
These finding provide evidence that Fxn knockdown does not substantially or chronically elevate
ROS in adult mice (Figure 6—figure supplement 3).
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Figure 4. Cardiopathology of frataxin knockdown mice. (a) Gomori’s iron staining and quantification of iron deposition in dox treated transgenic (Tg +),
wild-type (Wt +) and dox withdrawn transgenic (Tg ± Rescue) animals. Dox treated transgenic (Tg +) mice showing myocardial iron-overload (a) also
displayed altered expression of ferritin protein (b) which is involved in iron storage. Both iron-overload and ferritin protein levels were significantly lower
in Tg ± Rescue animals (a–b). (c) Masson’s trichrome staining and quantification showing increased fibrosis in Tg + mice when compared to Wt + and
Figure 4 continued on next page
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Gene expression changes due to frataxin knockdown
Given the phenotypic parallels in the cardiac and nervous system abnormalities in FRDAkd mice with
chronic Fxn reduction following treatment with dox, we next sought to explore genome wide molec-
ular mechanisms and determine which pathways were affected in the heart and nervous system, and
if they were reversible. We analyzed global gene expression profiles in the heart, cerebellum and
DRGs from Tg +, Tg -, Wt + and Tg ± mice treated for 0, 3, 12, 16, 20 weeks with dox and a rescue
cohort with 4 and 8 weeks post dox treatment (n = 192). Differential expression analyses
(Materials and methods) identified 1959 genes differentially expressed in Tg + mice heart when com-
pared to Wt + and Tg - mice (FDR < 5%, Figure 7a, Supplementary file 1). Similarly, we observed
709 and 206 genes differentially expressed in cerebellum and DRGs of Tg + mice, respectively
(Figure 7b). Although cross tissue overlap in expression changes was significant, the majority of
changes were tissue specific; only 31% and 38% of genes that were differentially expressed in the Tg
+ mice cerebellum and DRGs were also dysregulated in heart. Likewise, we only observed a 19%
overlap between differentially expressed genes in the DRG and cerebellum, consistent with previous
observations that Fxn reduction causes distinct molecular changes in different tissues
(Coppola et al., 2009).
Next, we analyzed these differently expressed transcripts in cardiac tissue from Tg + mice with
respect to cellular pathways. The top GO categories and KEGG pathways include chemotaxis,
immune response, lysosome and phagocytosis, vesicle transport and endocytosis, p53 signaling
pathway, cell cycle and division, protein transport and localization, nucleoside and nucleotide bind-
ing, and mitochondrion (Benjamini corrected p-value<0.05) (Figure 7a, Supplementary file 2). To
characterize the temporal patterns of these signaling cascades after frataxin knockdown and rescue,
we examined their time course by PCA analyses of the gene expression profiles (Figure 7c). By
examining the cumulative explained variability of the first three principal components for these clus-
ters of genes, we show that each of these functional groups are activated as early as three weeks
after dox initiation (and remain elevated for up to 20 weeks); importantly, the aberrant expression of
all of these clusters observed in Tg + mice are largely reversed after eight weeks of rescue via Fxn
re-expression (Figure 7a,b).
Another notable observation is that immune system activation is among the earliest pathways
regulated after Fxn knockdown (Figure 7c). This suggests that initiation of immune responses (innate
and adaptive) is a direct consequence of Fxn knockdown. For example, 38 genes involved in the che-
mokine signaling pathway (KEGG: mmu04062) were significantly differentially expressed due to Fxn
knockdown in Tg + mice heart (Figure 7—figure supplement 1). Cross validating these genes with
previously published gene expression datasets obtained from FRDA patients (Coppola et al., 2011)
and mouse models associated with FRDA (Miranda et al., 2002; Puccio et al., 2001), identified sev-
eral genes involved in the chemokine signaling pathway (E.g.: Ccl2, 3, 4, 7, Cxcl1, 16, Prkcd, Stat3)
consistently differentially expressed in these six independent FRDA associated datasets (Figure 7—
figure supplement 2). This implicates a vital role for chemokines and immune response in FRDA
pathology, as has been suggested for other neurodegenerative diseases (Cartier et al., 2005;
Andreasson et al., 2016; Fung et al., 2017; Leszek et al., 2016).
Figure 4 continued
Tg ± Rescue animals. (d) Electron micrographs of cardiac muscle from Wt +, Tg + and Tg ± Rescue animals at 20 week after dox treatment. Double
arrow lines indicate sarcomere. m = mitochondria. Scale bars, 1 mm. Data are representative of three biological replicates per group. (e) Higher
magnification of electron micrographs of cardiac muscle from Tg + mice, showing normal (m) and degenerating mitochondria (asterisks). (f) Aconitase
activity was assayed in triplicate in tissues removed from three hearts in each group. Values represent mean ±SME. One-way ANOVA test *p0.05.
DOI: https://doi.org/10.7554/eLife.30054.012
The following source data and figure supplement are available for figure 4:
Source data 1. This spreadsheet contains the raw signal intensity quantification data of ferric iron, ferritin and collagen staining which was used to gen-
erate the graphs shown in Figure 4a–c and the aconitase and citrate synthase enzymatic activity measurements are provided (Figure 4f).
DOI: https://doi.org/10.7554/eLife.30054.014
Figure supplement 1. Frataxin deficiency in mouse heart results in iron accumulation and increased levels of ferritin and ferroportin.
DOI: https://doi.org/10.7554/eLife.30054.013
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Figure 5. Frataxin knockdown mice exhibit neuronal degeneration. (a) Electron microscopic analysis of Wt +, Tg + and Tg ± rescue animal DRG
neurons at 20 week after dox treatment. Arrows indicate condensed mitochondria with empty vesicles. Insert in Tg + panel shows higher magnification
of electron micrographs of condensed mitochondria with empty vesicles in DRG neurons. Insert in Tg ± Rescue panel shows higher magnification of
abnormal mitochondria without cristae (asterisks). Nu = nucleus. (b) Higher magnification of electron micrographs of Tg + and Tg ± Rescue animal DRG
Figure 5 continued on next page
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Shared and tissue specific gene expression changes
We next performed weighted gene co-expression network analysis (WGCNA) (Zhang and Horvath,
2005; Langfelder and Horvath, 2008; Geschwind and Konopka, 2009), a powerful method for
understanding the modular network structure of the transcriptome, to organize the frataxin related
transcriptional changes in an unbiased manner following knockdown and rescue. WGCNA permits
identification of modules of highly co-expressed genes whose grouping reflects shared biological
functions and key functional pathways, as well as key hub genes within the modules, and has been
widely applied to understanding disease related transcriptomes (Zhang et al., 2013;
Parikshak et al., 2016). By applying WGCNA and consensus network analysis (Langfelder and Hor-
vath, 2008; Chandran et al., 2016), we identified 19 robust, reproducible co-expression modules
(Materials and methods; Figure 7—figure supplement 3 and Supplementary file 3) between the
three tissues datasets generated at 0, 3, 12, 16 and 20 weeks after Fxn knockdown and 4 and 8
weeks post dox removal. On the basis of the module eigengene correlation with time-dependent
changes after Fxn knockdown, we first classified modules as up-regulated and down-regulated fol-
lowing knockdown (Figure 7—figure supplement 4). Next, based on the significant module trait
relationships (Wilcoxon p-value<0.05), we identified 11 modules strongly associated with Fxn knock-
down: three down-regulated modules in two or more tissues after Fxn knockdown (yellow, light-
green and turquoise) and three up-regulated modules (blue, purple, and black) (Figure 7—figure
supplement 4). There also were three down-regulated modules in heart that were up-regulated in
cerebellum (red, greenyellow and magenta) and two up-regulated modules in heart that were down-
regulated in cerebellum (cyan and pink). Although six of the gene co-expression modules (yellow,
lightgreen, turquoise, blue, purple, and black) in the heart, cerebellum and DRG following Fxn
knockdown are highly preserved across tissues, five modules (red, greenyellow, magenta, cyan and
pink) exhibit differential expression profiles suggesting tissue specific molecular changes, consistent
with previous observations of shared and organ specific changes (Coppola et al., 2009) (Figure 7—
figure supplement 4).
As a first step toward functional annotation of the cross-tissue modules, we applied GO and
KEGG pathway enrichment analyses, which showed enrichment (Benjamini-corrected p values < 0.05)
for several GO categories and pathways in the Fxn knockdown co-expression modules which
included several previously associated functional categories related to current concepts of frataxin
function (Supplementary file 4). Three modules (yellow, lightgreen and turquoise) that were down-
regulated in two or in all three tissues due to Fxn knockdown included, nucleotide, nucleoside and
ATP binding, myofibril assembly, muscle tissue development, RNA processing, and several mito-
chondrial related categories: oxidative phosphorylation, respiratory chain, NADH dehydrogenase
activity, and electron transport chain. We also observed that the genes present in turquoise module
were enriched for several KEGG pathways, namely, PPAR signaling (mmu03320; genes = 14), insulin
signaling (mmu04910; n = 19), fatty acid metabolism (mmu00071; n = 10), cardiac muscle contrac-
tion (mmu04260; n = 20), dilated cardiomyopathy (mmu05414; n = 13), and hypertrophic
Figure 5 continued
neurons at 20 week after dox treatment. Tg + panel shows degenerating mitochondria and condensed mitochondria with empty vesicles in DRG
neurons. Tg ± Rescue panel shows two DRG neurons, one consisting of normal mitochondria (insert) and the other neuron with abnormal mitochondria
without cristae (insert). (c) Higher magnification of Tg + animals showing condensed mitochondria with empty vesicles in DRG neurons. (d) Higher
magnification of Tg ± rescue animals showing two DRG neurons, one consisting of normal mitochondria (normal DRG) and the other neuron with
abnormal mitochondria without cristae (affected DRG). (e) Insert images from c and d panels shows higher magnification of normal mitochondria (NM),
condensed mitochondria (CM), condensed mitochondria along with empty vesicles (CM + EV), and abnormal mitochondria without cristae (AM). (f)
Quantification of altered mitochondria in DRG neurons. Data are from multiple images from three biological replicates per group. Values represent
mean ± SME. Two-way ANOVA test *=P  0.05.
DOI: https://doi.org/10.7554/eLife.30054.015
The following source data and figure supplement are available for figure 5:
Source data 1. This spreadsheet contains the manual mitochondrial counting data from electron microscopy images of the DRG neurons which was
used to generate the graph shown in Figure 5f after frataxin knockdown in FRDAkd and control animals.
DOI: https://doi.org/10.7554/eLife.30054.017
Figure supplement 1. Nile Red staining labeling lipid droplets.
DOI: https://doi.org/10.7554/eLife.30054.016
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Figure 6. Frataxin knockdown mice exhibit neuronal degeneration in the spinal cord and retina. Electron microscopic analysis of Wt +, Tg + and Tg ±
rescue animal at 20 week after dox treatment. (a) Electron micrographs of spinal cord axon cross-section, displaying reduced myelin sheath thickness
and axonal cross-section area in Tg + and Tg ± Rescue animals. Bottom panel shows representative area utilized for quantification. (b–c) Quantification
of myelin sheath thickness and axonal cross-section area in the spinal cord. Data are from 2000 or more axons per group in the lumbar spinal cord
cross-section of high-resolution electron micrographs from three biological replicates per group. Values represent mean ±SME. One-way ANOVA test
*=P  0.05. (d) Electron micrographs of rod and cone photoreceptor cells, showing their disruption in Tg + animals (asterisks). (e) Retinal pigment
epithelium cell layer showing the presences of large vacuoles (arrows) in Tg + animals along with disruption in their photoreceptor cells (asterisks).
DOI: https://doi.org/10.7554/eLife.30054.018
The following source data and figure supplements are available for figure 6:
Figure 6 continued on next page
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cardiomyopathy (mmu05410; n = 14), which have been previously associated with FRDA, reflecting
the multi-systemic nature of FRDA. Similarly, three upregulated cross tissue modules (blue, purple,
and black) include, nucleotide binding, vesicle-mediated transport, immune response (innate and
adaptive), defense response, inflammatory response, induction of apoptosis, positive regulation of
cell death, cell adhesion, and skeletal system development (Supplementary file 4). These results
demonstrate that unsupervised analyses can identify groups of genes not only with shared biological
functions, but also relevant to the clinical phenotypes observed in FRDA.
Three tissue specific modules that were down-regulated in heart and up-regulated in cerebellum
(red, greenyellow and magenta) showed enrichment for, transcription regulator activity, neurological
system process, synaptic vesicle and nucleotide, nucleoside and ATP binding. Two other modules
that were up-regulated in heart and down-regulated in cerebellum (cyan and pink) were enriched for
cell cycle, cell division, mitosis and DNA replication (Supplementary file 4). In summary, we
observed several metabolic functional categories that were differentially expressed (up and down)
due to Fxn knockdown. The modules consisting of mitochondrial and cardiac specific categories
along with PPAR signaling, insulin signaling, fatty acid metabolism pathways were down regulated in
all tissues. Likewise, the modules enriched for immune, apoptosis and cell death related categories
we up-regulated in all tissues due to Fxn knockdown. Synaptic and transcription regulator activity
functional categories were only up-regulated in cerebellum, whereas cell cycle, cell division, mitosis
and DNA replication related functional categories were down-regulated in cerebellum and up-regu-
lated in the heart. These general functional categories related to Fxn knockdown have been previ-
ously associated with altered function in FRDA patients (Coppola et al., 2011; Haugen et al.,
2010), suggesting that genes within these modules would make interesting candidate genes for fol-
low up studies, because many of the genes have not been previously associated with FRDA pathol-
ogy and the disease mechanism.
Gene expression candidate biomarkers associated with frataxin
knockdown
To identify candidate molecular targets and to better understand the molecular pathophysiology
associated with Fxn knockdown, we first manually combined all the GO ontology terms (see above
and Supplementary file 4) that were enriched in the 11 modules into 26 broad functional categories
based on GO slim hierarchy (Supplementary file 5) and screened for co-expressed genes within
each functional category in all three tissues (r > 0.5 and p-value<0.05) over the time course. This
allowed us to identify critical functional sub-categories that are up or down regulated due to frataxin
knockdown and subsequently permitted us to detect differentially expressed candidate genes that
are co-expressed within each functional category (Figure 7d; Figure 7—figure supplement 5). For
example, we show that immune, cell cycle and apoptosis related functional groups are up-regulated,
whereas cardiac and mitochondrial related functional groups were down-regulated (Figure 7d). In
the immune category, we observed most prominent changes in complement activation pathway
genes, namely, C3, C4b, C1qb, C1qc and Serping1. Interesting, we also observed that many of
these genes were also up-regulated in peripheral blood mononuclear cells obtained from FRDA
patients (Figure 7—figure supplement 6), suggesting the potential for complement activation to
act as a biomarker for FRDA as previously suggested for other degenerative diseases (Aiyaz et al.,
2012). Similarly, we found several genes, for example, Cacna2d1, Abcc9 and Hrc involved in normal
Figure 6 continued
Source data 1. This spreadsheet contains the image analyses quantification data from electron microscopy images of the spinal cord axons which was
used to generate the graph shown in Figure 6b and c after frataxin knockdown in FRDAkd and control animals.
DOI: https://doi.org/10.7554/eLife.30054.022
Figure supplement 1. Frataxin knockdown in adult mice does not change the numbers of Purkinje cells and thickness of granular layer of the
cerebellum.
DOI: https://doi.org/10.7554/eLife.30054.019
Figure supplement 2. PDK1 and Mef3 pathway is not activated in Fxn knockdown mice.
DOI: https://doi.org/10.7554/eLife.30054.020
Figure supplement 3. Quantification of reactive oxygen species (ROS) levels in Fxn knockdown animals.
DOI: https://doi.org/10.7554/eLife.30054.021
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Figure 7. Gene expression analysis of frataxin knockdown mice. (a) Heat map of significantly up- and down-
regulated genes (rows) in heart tissue of Tg + mice from 0, 3, 12, 16, 20 and plus 4, 8 weeks post dox treatment
relative to controls are grouped into 13 functional categories. (b) Summary of differentially expressed genes during
Fxn knockdown and rescue in heart, cerebellum and DRG tissues from four biological replicates. (c) Cumulative
percent of variability in Tg + gene expression data explained by the first three principal component for each
functional category. (d) Networks highlighting differentially expressed genes due to Fxn knockdown in Tg + mice
for selected functional categories. Nodes represents genes and edges are present between nodes when their
gene expression correlation is greater than 0.5. Mouse gene names are displayed in upper case for clarity
purpose. Node size and color (red = up regulation and green = down regulation) denotes extent of differential
expression.
Figure 7 continued on next page
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cardiac function, to be down-regulated in heart tissue upon frataxin knockdown (Figure 7d). CAC-
NA2D1 is associated with Brugada syndrome, also known as sudden unexpected nocturnal death
syndrome, a heart condition that causes ventricular arrhythmia (Risgaard et al., 2013). Mutations in
ABCC9 gene can cause dilated cardiomyopathy (Bienengraeber et al., 2004) and a genetic variant
in the HRC gene has been linked to ventricular arrhythmia and sudden death in dilated cardiomyop-
athy (Singh et al., 2013). These observations suggest that lower levels of frataxin causes dysregula-
tion of multiple genes related to arrhythmia or cardiac failure, a primary cause of death in FRDA
patients.
There has been accumulating evidence suggesting that apoptosis may be an important mode of
cell death during cardiac failure (Gonza´lez et al., 2003). In agreement with this, we observed genes
related to apoptosis were up-regulated after Fxn knockdown in FRDAkd mice heart (Figure 7d),
which has been previously associated with FRDA pathogenesis and reported in other Fxn deficiency
models (Simon et al., 2004; Huang et al., 2009; Bolinches-Amoro´s et al., 2014). In order to vali-
date our network findings, we tested CASP8 protein levels (Muzio et al., 1996), observing an
increase in cleaved Caspase eight protein levels in Tg + heart tissue compared with control mice
(Figure 8a). Next, we employed the TUNEL assay to detect apoptotic cells that undergo extensive
DNA degradation during the late stages of apoptosis (Kyrylkova et al., 2012). However, we did not
observe an increase in cell death in all tissues by TUNEL staining (Figure 8b).
Literature data extraction for candidate genes associated with frataxin
knockdown
We next examined the phenotype-gene associations extracted by co-occurrence-based text-mining
in an attempt to link FRDA disease phenotypes with genes. For this, we screened the literature for
potential co-occurrence link association between the observed FRDAkd mice phenotypes and the
genes that are differentially expressed after Fxn knockdown (Materials and methods). Identifying
potential biomarker candidates that are previously validated for certain phenotypes can provide
insight into disease progression, pathogenesis and extremely valuable for assessing therapeutic
options (Trugenberger et al., 2013). We screened with the genes that are differentially expressed
(FDR < 5%) and present in the co-expression modules associated with behavioral and pathological
key-terms (Eg: ataxia; Supplementary file 6) in the published literature. Interestingly, this analysis
identified numerous genes in which mutations are known to cause Mendelian forms of ataxia namely,
ANO10 (Vermeer et al., 2010; Misˇkovic´ et al., 2016), CABC1 (Mollet et al., 2008; Gerards et al.,
Figure 7 continued
DOI: https://doi.org/10.7554/eLife.30054.023
The following source data and figure supplements are available for figure 7:
Source data 1. This spreadsheet contains the number of genes differentially expressed in the microarray data
from heart, cerebellum and DRGs after frataxin knockdown in FRDAkd and control animals (Figure 7b) and the
cumulative percent of variability data from PCA analyses is also provided which was used to generate the graph
shown in Figure 7c.
DOI: https://doi.org/10.7554/eLife.30054.030
Figure supplement 1. Chemokine signaling pathway is altered in frataxin knockdown mice.
DOI: https://doi.org/10.7554/eLife.30054.024
Figure supplement 2. Chemokine signaling pathway is altered in FRDA patients and mouse models.
DOI: https://doi.org/10.7554/eLife.30054.025
Figure supplement 3. Identification of frataxin knockdown specific modules using WGCNA.
DOI: https://doi.org/10.7554/eLife.30054.026
Figure supplement 4. WGCNA identifies consensus co-expression modules associated with frataxin knockdown
and rescue.
DOI: https://doi.org/10.7554/eLife.30054.027
Figure supplement 5. Co-expression analyses reveals functional categories associated with frataxin knockdown
and rescue.
DOI: https://doi.org/10.7554/eLife.30054.028
Figure supplement 6. Frataxin knockdown alters complement activation pathway genes in adult mice.
DOI: https://doi.org/10.7554/eLife.30054.029
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Figure 8. Gene expression candidate biomarkers in frataxin knockdown mice. (a) Western blot analyses of Caspase 8, XN nd LC3 following 20 weeks
with or without dox treatment in heart. (b) TUNEL assay of heart, spinal cord and DRG neurons at 20 weeks after dox treatment in Tg + mice. (c)
Literature associated gene networks highlighting differentially expressed genes due to Fxn knockdown in Tg + mice for selected key-terms. Nodes
represents genes which has pairwise correlation greater than 0.5 with Fxn gene and edge size represents strength of their gene expression correlation.
Figure 8 continued on next page
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2010) and POLG (Schicks et al., 2010; Synofzik et al., 2012) that were significantly down-regulated
in the heart tissue and slightly down-regulated in the cerebellum after Fxn knockdown in Tg + ani-
mals (Figure 8c and Figure 8—figure supplement 1). We also found three other genes that are dif-
ferentially expressed due to Fxn knockdown, namely, CSTB (Pennacchio et al., 1998), NHLRC1
(Singh and Ganesh, 2009) and PMM2 (Matthijs et al., 1997) all of which are associated with other
disorders manifesting ataxia (Figure 8c). These observations suggest that Fxn along with multiple
other downstream candidates causes behavioral deficits in FRDAkd mice. Similarly, for cardiac phe-
notypes, we identified multiple genes related to cardiac fibrosis that were up-regulated in FRDAkd
mice heart (Figure 8c), including Lgals3 (Sygitowicz et al., 2016), Icam1 (Salvador et al., 2016) and
Timp1 (Polyakova et al., 2011)(Figure 8c). Genes related to iron regulation, included Hfe (Del-Cas-
tillo-Rueda et al., 2012), Slc40a1 (Del-Castillo-Rueda et al., 2012), Hmox1 (Song et al., 2012), Tfrc
(Del-Castillo-Rueda et al., 2012) and Gdf15 (Cui et al., 2014), all of which are directly involved in
hemochromatosis and iron overload (Figure 8c). We also found previously associated genes related
with muscle strength (E.g.: Srl, Dcn), myelination (E.g.: Pmp22, Lgals3, Tlr2 and Sirt2) and several
genes related to neuronal degeneration (E.g.: Grn and App) to be dysregulated in FRDAkd mice
(Figure 8c and Figure 8—figure supplement 1), connecting this degenerative disorder with the
molecular signaling pathways known to be causally involved in other such disorders.
One pathway that was dysregulated and increasingly associated with neurodegeneration, was
autophagy, since several autophagy-related genes (Lamp2, Atf4, Tlr2, Optn, Mapk14, Sirt2, Icam1,
Lgals3, Dcn, Rcan1, Grn) were present in these disease phenotype-associated sub networks
(Figure 8c). Autophagy is responsible for the recycling of long-lived and damaged organelles by
lysosomal degradation (Gustafsson and Gottlieb, 2009) and is associated with various stress condi-
tions including mitochondrial dysfunction (Pavel and Rubinsztein, 2017; Bento et al., 2016). Disrup-
tion of autophagy is also reported as altered in other Fxn deficiency models (Simon et al., 2004;
Huang et al., 2009; Bolinches-Amoro´s et al., 2014). To validate our network findings, we utilized
LC3-II as a marker for autophagy, showing autophagy activation in Tg + mice heart, but not in spinal
cord (Figure 8a,d). This suggests activation of apoptosis (Figures 7d and 8a) and autophagy
(Figure 8a,d) may therefore potentiate the cardiac dysfunction of Tg + mice. Next, by examining
the expression levels of all these sub-network genes (Figure 8c) in the datasets of other FRDA
related mouse models (Miranda et al., 2002; Puccio et al., 2001) and patient peripheral blood
mononuclear cells (Coppola et al., 2011), we show that they are also differentially expressed in the
same direction in majority of the samples (Figure 8e). In contrast, in two asymptomatic mouse mod-
els (KIKO and KIKI) with frataxin reduction below the threshold necessary to produce phenotype
(Miranda et al., 2002), most of the gene expression changes observed here in this symptomatic
model are not recapitulated (Figure 8e). This suggests that these sub network genes may be strong
candidates for molecular biomarkers in FRDA. In summary, consistent with our behavioral, physiolog-
ical and pathological findings, we show multiple candidate genes related to key degeneration
related phenotypes to be altered in FRDAkd mice.
Figure 8 continued
Node size correspond to number of PubMed hits with co-occurrence of gene and its corresponding key-term. Node color represents up-regulated (red)
and down-regulated (green). Gene names are displayed in upper case for clarity purpose. (d) Representative images and quantification of LC3 staining
in heart tissue at 20 weeks after dox treatment. Values represent mean from three biological replicates per group ±SME. One-way ANOVA test
*=P  0.05. (e) Heat map depicting expression of key genes (rows) across samples (columns) for seven groups (red corresponds to gene up-regulation
and blue to down-regulation). The seven groups represents: (i) ataxia, (ii) cardiac fibrosis, (iii) excess iron overload, (iv) muscular strength, (v) myelin
sheath, (vi) neuronal degeneration and (vii) autophagy related genes. The column represents seven independent datasets obtained from, FRDAsh mice,
cardiac specific knockout mice (Puccio et al., 2001), knock-in knockout mice (Miranda et al., 2002), knock-in mice (Miranda et al., 2002) and patient
peripheral blood mononuclear cells (Coppola et al., 2011).
DOI: https://doi.org/10.7554/eLife.30054.031
The following source data and figure supplement are available for figure 8:
Source data 1. This spreadsheet contains the raw signal intensity quantification data of LC3 staining which was used to generate the graph shown in
Figure 8d.
DOI: https://doi.org/10.7554/eLife.30054.033
Figure supplement 1. Literature mining identifies genes associated with frataxin knockdown and observed phenotype in FRDAkd mice.
DOI: https://doi.org/10.7554/eLife.30054.032
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Rescue of behavioral, pathological and molecular changes due to
frataxin restoration
Our data show that mice carrying the dox inducible shRNA for Fxn develop normally until they are
challenged with dox, which subsequently results in substantial FXN reduction and causes multiple
behavioral and pathological features observed in patients with FRDA, including cardiac and nervous
system dysfunction (Figures 2–6). Fxn knockdown mice displayed remarkable parallels with many of
the behavioral, cardiac, nervous system impairments along with physiological, pathological and
molecular deficits observed in patients. At a general level, FRDAkd mice displayed weight loss,
reduced locomotor activity, reduced strength, ataxia and early mortality (Figure 2). In the nervous
system, FRDAkd mice showed abnormal mitochondria and vacuolization in DRGs, retinal neuron
degeneration, and reduced axonal size and myelin sheath thickness in the spinal cord (Koeppen and
Mazurkiewicz, 2013; Koeppen, 2011; Simon et al., 2004; Perdomini et al., 2013) (Figures 5 and
6). With regards to cardiac dysfunction, FRDAkd mice exhibited conduction defects, cardiomyopa-
thy, evidence of iron overload, fibrosis, and biochemical abnormalities that are commonly observed
in patients ( (Koeppen and Mazurkiewicz, 2013; Koeppen, 2011; Perdomini et al., 2013) Figures 3
and 4). These features correspond to a phenotype of substantial multisystem, clinical disability con-
sistent with moderate to severe disease after three months of frataxin deficiency and that lead to a
50% mortality rate at approximately five months in these mice.
Given that optimal therapy in patients with FRDA could be considered replenishment of FXN
itself, e.g. via gene therapy (Perdomini et al., 2014) or improvement of Fxn transcription via small
molecules (Gottesfeld et al., 2013), we asked how much of the behavioral, physiological, pathologi-
cal and molecular phenotype(s) observed at this relatively severe stage of illness could be reversed
following such ‘optimal’ therapy. In this case, optimal therapy is return of normal FXN levels under
endogenous regulation through relief of exogenous inhibition. Answering this question of reversibil-
ity is crucial for any clinical trial, whatever the mechanism of action of the therapy, since we currently
have limited information as to what represents potentially reversible neurologic or cardiac
phenotypes.
To address this, we compared two groups of mice, both transgenic and treated with dox for 12
weeks, at which time both groups show equivalent levels of substantial clinical features (Figure 2—
figure supplement 2). In one, Tg + the dox is continued for another 12 or more weeks, and in the
other Tg ± the dox is removed and the animals are followed. Restoration of FXN expression in Fxn
knockdown mice (Tg ±) that had reached a level of substantial clinical dysfunction led to significant
improvement in lifespan (no death until 20 weeks post dox removal) when compared to Tg + group,
which resulted in a 90% mortality rate by 25 weeks after dox treatment initiation (Figure 2b). Rescue
animals (Tg ±) also displayed rapid improvement in: gait ataxia, body weight, muscle strength, loco-
motor activity, and balance on rotarod test over the ensuing 12 week period, to a point where the
treated animals were not significantly different from controls on many tests (Figure 2). Remarkably,
we observed all of the six FRDA associated clinical phenotypes tested showed significant improve-
ment, suggesting that FRDA-like neurological defects due to absence of the mouse Fxn gene can be
rectified by delayed restoration of Fxn (Figure 2).
We next sought to determine whether the observed reversible behavioral changes in FRDAkd
mice are also accompanied by recovery of the physiological phenotype in FRDAkd mice heart, since,
changes in physiology offer attractive therapeutic targets for symptomatic and preventive treatment
of ataxia. Tg ± mice that received the dox for 12 weeks followed by 12 weeks dox removal displayed
reversal of the long QT interval phenotype, when compared to Tg + mice at both 12 and 24 weeks
post dox treatment initiation (Figure 3a,b,e). We observed ventricular and posterior wall thickening
only at 24 weeks post dox treatment in Tg + animals (Figure 3d,f,g), suggesting that long QT inter-
val phenotype is a earlier manifestation of disease that occurs before left ventricular wall thickening.
Correcting this aberrant physiology through activation of Fxn gene expression is a potential early
therapeutic biomarker.
One question that intrigued us because of the striking behavioral and physiological functional
recovery is to what extent frataxin deficiency-associated phenotypes represented pathological find-
ings related to cell dysfunction (potentially reversible) versus cell death (irreversible) recovery. Patho-
logical and biochemical analyses in Tg ± mice heart following 8 weeks of dox withdrawal revealed
improved cardiac function and reduced iron and ferritin accumulation, myocardial fibrosis, well-
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ordered sarcomeres, normal aconitase activity and reduced mitochondrial abnormalities (Figure 4).
Relevant to the pathogenesis of FRDA heart and the role of iron and mitochondrial defect, it has
been found that cells with these defects are sensitized to cellular dysfunction (Delatycki et al.,
1999; Michael et al., 2006), and here we show this can be ameliorated by Fxn restoration.
In the nervous system of Tg ± mice 8 weeks after dox removal, we observed reduced empty
vesicles and fewer condensed, degenerating mitochondria in DRG neurons along with several abnor-
mal mitochondria (empty and without cristae) containing DRG neurons compared with those in which
dox was continued (Figure 5a–f). We only observed mild improvement in myelin sheath thickness
and cross section axonal size in the spinal cord of Tg ± mice during this time period (Figure 6a–c).
Conversely, we observed a significant reduction in the number of vacuoles and disrupted photore-
ceptors in the retina of Tg ± mice, indicating that Fxn restoration rescued photoreceptor degenera-
tion (Figure 6d,e). These findings establish the principle of cellular dysfunction reversibility in
FRDAkd mouse model due to Fxn restoration and, therefore, raise the possibility that some neuro-
logical and cardiac defects seen in this model and FRDA patients may not be permanent.
In line with remarkable recovery of several behavioral, physiological and pathological defects in
FRDAkd mice, we also observed that the genome-wide molecular biomarker represented by gene
expression changes accompanying Fxn knockdown could be completely rescued after Fxn restora-
tion (Figure 7). By rescuing the FXN protein levels back to the near basal level, we were able to
reverse the molecular changes completely. After 8 weeks of dox removal following an initial 12
weeks of dox treatment, we examined the number of differentially expressed genes (at FDR < 5%) in
all tissues and observed 100% normalization of gene expression levels in cerebellum and DRGs, and
99.95% of gene expression levels in the heart of FRDAkd mice (Figure 7a,b). These results, which
included several pathways (Figure 7a,c,d) that are significantly affected due to Fxn depletion and
that show complete reversal (Figure 7a,b) due to Fxn restoration may provide a gene-expression
signature for evaluation of various therapeutic paradigm.
In summary, all six major behavioral deficits in FRDAkd mice were reversed (Figure 2). In the car-
diac system, the long QT interval phenotype along with various pathological manifestations, includ-
ing mitochondrial defects were reversed. In the nervous system, we observed improvement in DRGs
and photoreceptor neurons, and complete reversal of the molecular changes in all three tissues sug-
gesting near basal Fxn levels are sufficient to alleviate behavioral symptoms in the preclinical
FRDAkd model. The rapidity of Fxn expression due to dox removal and its robust correction of vari-
ous parameters, even when restored after the onset of motor dysfunction, makes this FRDAkd
mouse model an appealing potential preclinical tool for testing various therapeutics for FRDA.
Discussion
Here we report development and extensive characterization of a novel, reversible mouse model of
FRDA based on knock-down of frataxin by RNA interference (Seibler et al., 2007), the FRDAkd
mouse. Treated transgenic mice developed abnormal mitochondria, exhibit cardiac and nervous sys-
tem impairments along with physiological, pathological and molecular deficits. These abnormalities
likely contributed to the behavioral phenotype of FRDAkd mice, parallel to what is observed in
FRDA patients (Koeppen and Mazurkiewicz, 2013; Koeppen, 2011). Importantly, restoration of
Fxn expression, even after the development of severe symptoms and pathological defects, resulted
in a drastic amelioration of the clinical phenotype, both in the cardiac and nervous systems, including
motor activity. Pathology was significantly improved in the heart, DRGs and in the retina, but only
mild improvement was observed in spinal cord, suggesting Fxn restoration for the duration of 8
weeks is not sufficient for reversal of neuronal defects in the spinal cord after Fxn knockdown. Inter-
estingly, transcriptomic changes due to Fxn knockdown in three different tissues differed
(Coppola et al., 2009), indicating variable response to frataxin deficiency, which could partly explain
cell and tissue selectivity in FRDA (Lynch et al., 2012). The onset and progression of the disease cor-
relates with the concentration of doxycycline (shRNA induction), and the phenotype returns to base-
line after its withdrawal. Since off-target effects due to the shRNA induction are of concern in any
RNAi based experiments, we examined the off-target effect by determining the shRNA specificity
and measuring changes in gene expression pattern during the induction of shRNA expression target-
ing the Fxn gene. Fxn was the earliest and most consistent gene showing significant down-regulation
and we did not observe any changes in the RNA levels of other potential targets at any stage in our
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analyses, indicative of the absence of significant off-target effects. The onset of transgene expression
to achieve Fxn knockdown and robust recovery of symptoms due to restoration of Fxn levels in a
mouse model of FRDA, even when reversed after the onset of the disease, makes this model an
appealing potential preclinical tool for developing FRDA therapeutics. This approach will also enable
new insights into FRDA gene function and molecular disease mechanisms.
Several models of FRDA have been developed and each have advantages and disadvantages
(Perdomini et al., 2013). This new FRDAkd model exhibits several unique features that provide
advantages for the study of FRDA pathophysiology relative to other existing models (Miranda et al.,
2002; Al-Mahdawi et al., 2004; Al-Mahdawi et al., 2006; Puccio et al., 2001; Simon et al., 2004;
Perdomini et al., 2013). First, induction of frataxin knockdown permits circumventing potential con-
founding developmental effects (Cosse´e et al., 2000) and has the flexibility to enhance the disease
onset and progression very rapidly by increasing the doxycycline dose. Moreover, the temporal con-
trol of Fxn knockdown can provide further insights into the sequence of tissue vulnerability during
the disease progression (Lynch et al., 2012). Second, reversibility of Fxn knockdown provides a
unique model to mimic the effect of an ideal therapeutic intervention. Along this line, it has so far
not been established to what extent FXN restoration after the onset of clinical motor symptoms is
successful to prevent occurrence and/or progression of FRDA. Therefore, this model will be of cen-
tral importance to gain better insights into disease pathogenesis and to test therapeutic agents.
Third, the doxycycline-dependent reduction of Fxn expression can be tailored to carefully determine
the critical threshold of Fxn levels necessary to induce selective cellular dysfunction in the nervous
system (DRGs and spinal cord) and to understand the occurrence of tissue specific dysfunction in
FRDA. Thereby, these experiments will help to understand the tissue specificity and generate clini-
cally relevant tissue targeted therapeutics for FRDA. Finally, the temporal control of single copy and
reversible regulation of shRNA expression against Fxn produces reproducible transgene expression
from the well-characterized rosa26 locus to generate the first model to exhibit and reverse several
symptoms parallel to FRDA patients. Here, we focused on the consequences of frataxin removal in
an otherwise healthy adult animal. However, we should emphasize that this FRDAkd model uniquely
facilitates future studies exploring prenatal or early post natal knockdown, and a wide variety of time
course studies to understand disease pathophysiology and to identify potential imaging, physiologi-
cal, or behavioral correlates of likely reversible or non-reversible disabilities in patients.
We show that FRDAkd animals are defective in several behaviors and exhibit weight loss, reduced
locomotor activity, reduced strength, ataxia and early mortality. All of these defects were signifi-
cantly improved following Fxn restoration, approaching or reaching wild-type levels. Most impor-
tantly ataxia and survival are well-established and important clinical endpoints in FRDA (Tsou et al.,
2011), readouts after Fxn restoration clearly improve these parameters and appear to be directly
related to the functional status of the FRDAkd mice. We conclude that Fxn deficient mice exhibit
considerable neurological plasticity even in a nervous system that is fully adult. Hence, utilizing these
reversible intermediate behavioral phenotypes as biomarkers will help us determine the disease pro-
gression and test various FRDA treatment options in this model.
Hypertrophic cardiomyopathy is a common clinical feature in FRDA and approximately 60% of
patients with typical childhood onset FRDA die from cardiac failure (Tsou et al., 2011). It is generally
believed that cardiac failure is caused by the loss of cardiomyocytes through activation of apoptosis
(Fujita and Ishikawa, 2011). We observed activation of early apoptosis pathways in heart tissue and
severe cardiomyopathy characterized by ventricular wall thickness (Bennett, 2002). However, we did
not observe TUNEL positive cells in either heart or nervous system. This may reflect that the model
is in a early phase of cell death initiation, or rather that apoptotic cells are readily phagocytosed by
neighboring cells and are consequently difficult to detect (Ravichandran, 2011). We also observed
enhanced activation of autophagy in the heart tissue of FRDAkd mice, where autophagic cardiomyo-
cytes are observed at a significantly higher frequency during cardiac failure (Martinet et al., 2007).
These results suggest that apoptosis and autophagy together might synergistically play a vital role in
the development of cardiac defect in FRDA (Eisenberg-Lerner et al., 2009).
During Fxn knockdown, FRDAkd mice initially exhibited a long QT interval at 12 weeks during
electrocardiographic analyses, followed by the absence of P-waves and increased ventricular wall
thickness at 24 weeks. Restoration of Fxn levels at 12 weeks reversed long QT interval phenotype.
However, it will be interesting to examine if the ventricular wall thickness can be restored by a more
prolonged rescue time period. Another prominent feature of Fxn deficiency mouse and FRDA
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patients is iron accumulation and deficiency in activity of the iron-sulfur cluster dependent enzyme,
aconitase, in cardiac muscle (Puccio et al., 2001; Ro¨tig et al., 1997; Delatycki et al., 1999;
Michael et al., 2006). Consistent with these observations, we observed increased iron accumulation
and reduced aconitase activity in the cardiac tissue of FRDAkd mice and we demonstrate a marked
reversal of both to a statistically significant extent, suggesting Fxn restoration is sufficient to over-
come and clear the iron accumulation and reverse aconitase activity (Tan et al., 2001). Our gene
expression data revealed several genes (Hfe [Del-Castillo-Rueda et al., 2012], Slc40a1 [Del-Castillo-
Rueda et al., 2012], Hmox1 [Song et al., 2012], Tfrc [Del-Castillo-Rueda et al., 2012] and Gdf15
[Cui et al., 2014]) directly involved in hemochromatosis and iron overload to be upregulated in our
FRDAkd mice, all of which were rescued to normal levels by frataxin restoration. Similarly, several
downregulated genes involved in normal cardiac function (Cacna2D1, Abcc9 and Hrc) were rescued
by Fxn restoration. Together, these data indicate that Fxn restoration in symptomatic FRDAkd mice
reverses the early development of cardiomyopathy at the molecular, cellular and physiological
levels.
Cellular dysfunction due to FXN deficiency is presumed to be the result of a mitochondrial defect,
since FXN localizes to mitochondria (Tan et al., 2001; Koutnikova et al., 1997; Foury and Cazza-
lini, 1997) and deficiencies of mitochondrial enzymes and function have been observed in tissues of
FRDA patients (Ro¨tig et al., 1997; Lodi et al., 1999). It has been hypothesized that FXN deficiency
induced mitochondrial dysfunction involves the production of ROS, which subsequently lead to cellu-
lar dysfunction (Tamarit et al., 2016; Santos et al., 2010). Several studies have suggested the exis-
tence of ROS markers in FRDA patient samples (Schulz et al., 2000; Tozzi et al., 2002;
Piemonte et al., 2001; Emond et al., 2000). However, other evidence from several different FRDA
model organisms suggests that ROS are not elevated (Chen et al., 2016a; Chen et al., 2016b;
Seznec et al., 2005; Shidara and Hollenbeck, 2010) and more than ten clinical trials based on anti-
oxidant therapy have shown no or limited benefit in FRDA patients (Kearney et al., 2012). In our
FRDAkd mouse model, we did not observe evidence of a chronic, sustained increase in ROS as mea-
sured by three different assays, which is consistent with recent data suggesting that FXN deficiency
likely acts via other pathways (Chen et al., 2016a; Chen et al., 2016b). Here we show that FRDAkd
mice displayed accumulation of damaged mitochondria, and reduced aconitase as a direct conse-
quence of frataxin deficiency in heart, consistent with previous findings in conditional FRDA mouse
models (Puccio et al., 2001; Simon et al., 2004). This is consistent with the model whereby frataxin
deficiency inhibits mitochondrial function leading to cellular dysfunction (Gonza´lez-Cabo and Palau,
2013). Restoration of FXN resulted in improvement in pathological mitochondrial structure indicat-
ing that FXN restoration prevents mitochondrial defects and may thereby enhance cell survival
(Tan et al., 2001). Our observation of mitochondrial dysfunction recovery as early as eight weeks
after FXN restoration is consistent with the highly dynamic nature of mitochondrial function
(Chan, 2012).
In the nervous system, we observed higher level of condensed mitochondria in DRGs through
ultrastructural analyses. Condensed mitochondria are known to have lower respiratory control and
ATP production (Desagher and Martinou, 2000). On most occasions, these condensed mitochon-
dria in DRG neurons of FRDAkd mice were associated with electron-light, or ‘empty’ vesicles.
Degenerating mitochondria in the nervous system can lose their cristae to become empty vesicles
co-occurring with either lipid, pigment, and glycogen accumulation, may be the case here
(Golestaneh et al., 2017). Nile Red staining in the FRDAkd mice was performed to examine if these
empty vesicles are lipid bodies. However, while we observed lipid accumulation in these vesicles in
the liver, we did not observe detectable levels of lipid staining in the DRGs, heart and spinal cord
samples in either control or transgenic animals. Consistent with a mitochondrial origin for these
vesicles, we did observe a reduction in condensed mitochondria and their association with these
empty vesicles in rescue animals, suggesting that a substantial fraction of dysfunctioning frataxin-
deficient mitochondria containing neurons are still viable after the onset of disease and that their
dysfunction can be reversed. Additional experiments will be needed to identify the origin and com-
position of these empty vesicles in this model.
In the spinal cord, we observed reduction of axonal size and myelin sheath thickness in FRDAkd
animals, however after eight weeks of rescue period by FXN restoration, we observed limited
improvement, suggesting more time may be necessary for improved nervous system recovery. Con-
versely, disruption of photoreceptor neurons and degenerating RPE cells in the retina displayed
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robust recovery, indicating an overall morphological improvement in retinal neurons upon FXN res-
toration to normal levels. These findings extend previous studies showing that many defects in
FRDA cells in vitro and cardiac function in vivo may be reversible following reintroduction of FXN
(Vyas et al., 2012) by pharmacological interventions targeting aberrant signaling processes
(Rufini et al., 2015) or by reintroduction of FXN by gene therapy (Perdomini et al., 2014).
Improved understanding of the mechanism by which FXN deficiency leads to the various pheno-
types observed in FRDA is a major goal of current research in this disorder. In this regard, gene
expression analyses identified several pathways altered, including the PPAR signaling pathway, the
insulin signaling pathway, fatty acid metabolism, cell cycle, protein modification, lipid metabolism,
and carbohydrate biosynthesis, all of which have been previously associated with altered function in
FRDA patients (Coppola et al., 2009; Haugen et al., 2010; Coppola et al., 2006). Although we did
observe iron deposition associated with Fxn knockdown, we did not observe, strong evidence of
Pdk1/Mef2 activation, as previously observed in the fly and a constitutive mouse model (Chen et al.,
2016a; Chen et al., 2016b). This observation may be due to differences in the timing of knockdown.
The role of this specific pathway in mediating neurodegeneration needs further exploration following
embryonic or early postnatal knockdown in our model and in others. We also observed several
immune components, namely, complement and chemokine cascade genes being upregulated, may
be implicated as a protective mechanism after Fxn knockdown, or in a causal role through chronic
activation of the inflammatory response (Shen et al., 2016; Lu et al., 2009). It will be interesting to
assess the causal roles of these genes and pathways and as potent candidate biomarkers for FRDA
at several stages during the disease progression.
Determining definitively whether the global expression changes observed in this study are pri-
mary or secondary to Fxn knockdown will require further investigation by examining more dense
time points immediately after Fxn knockdown and rescue, but our data clearly support the utility of
induced models of disease, whereby the consequences of gene depletion can be more cleanly con-
trolled to examine the molecular changes (Seibler et al., 2007). Together with post-induction res-
cue, this study highlights potential biomarkers and pathways of FRDA progression. For FRDA clinical
trials, it will be important to assess whether these expression changes are translatable to the human
disease and extend to other tissues that are more easily accessible than CNS or cardiac tissue.
Together, these observations suggest that this work also provides a functional genomics foundation
for understanding FRDA disease mechanism, progression and recovery.
In conclusion, we characterize a new, inducible model of Fxn deficiency and provide multiple lines
of evidence that Fxn knockdown in adult mice leads to clinical – pathological features parallel to
those observed in FRDA patients. By restoring FXN levels we show reversal of several symptoms
even after significant motor and cardiac abnormalities, demonstrating that substantial clinical symp-
toms may result from reversible cellular dysfunction, rather than cell death. These data also highlight
the utility of this model for testing potential therapeutics, such as gene therapy (Perdomini et al.,
2014), protein replacement therapy (Vyas et al., 2012), enhancement of mitochondrial function
(Strawser et al., 2014) and small molecules (Sandi et al., 2014; Kearney et al., 2016). In fact, our
findings suggest that such approaches may not only enhance FXN expression and rescue down-
stream molecular changes, but may too alleviate pathological and behavioral deficits associated with
FRDA, depending on the stage of the disorder.
Materials and methods
Key resources table
Reagent type (species)
or resource Designation Source or reference Identifiers Additional information
strain, strain background
(M. musculus)
FRDAkd mice
(in C57BL/6 background)
this paper Frataxin knockdown mice
strain, strain background
(M. musculus)
C57BL/6J The Jackson Lab RRID:IMSR_JAX:000664
cell line (M. musculus) Neuro-2a cell lines
(ATCC CCL-131)
ATCC ATCC CCL-131;
RRID:CVCL_0470
Continued on next page
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Continued
Reagent type (species)
or resource Designation Source or reference Identifiers Additional information
cell line (M. musculus) LW-4 (129SvEv)
embryonic stem cells
UCLA Transgenic Core facility ES cell generated at UCLA
from 129SvEv mice
chemical compound,
drug
Doxycycline (Dox) Sigma D9891-100G Doxycycline hyclate
commercial assay or kit Bradford assay Bio-Rad 500–0006 Bio-Rad Protein Assay Dye
Reagent Concentrate
commercial assay or kit Aconitase assay kit Cayman Chemical 705502
commercial assay or kit Citrate synthase assay kit Sigma CS0720
commercial assay or kit RNA extraction kit Qiagen 217004 miRNeasy mini kit
commercial assay or kit RNA reverse transcription kit ThermoFisher Scientific 18091050 SuperScript IV First-Strand
Synthesis System
commercial assay or kit TUNEL assay Roche 11767291910 in Situ Cell Death
Detection Kit, Fluorescein
commercial assay or kit OxyBlot assay Millipore S7150 OxyBlot Protein Oxidation
Detection Kit
antibody anti-ferroportin-1 LifeSpan BioSciences LS-B1836
RRID:AB_2254938
Rabbit, 1:200
antibody anti-ferritin Abcam ab69090
RRID:AB_1523609
Rabbit, 1:500
antibody anti-LC3 Abgent AM1800a
RRID:AB_2137696
Mouse, 1:200
antibody anti-NeuN EMD Millipore ABN91
RRID:AB_11205760
Chicken, 1:500
antibody anti-NeuN EMD Millipore ABN78
RRID:AB_10807945
Rabbit, 1:500
antibody Alexa Fluor 488 ThermoFisher Scientific A-11008
RRID:AB_143165
Goat anti-rabbit IgG, 1:500
antibody Alexa Fluor 594 ThermoFisher Scientific A-11039
RRID:AB_142924
Goat anti-chicken IgG, 1:500
antibody Alexa Fluor 488 ThermoFisher Scientific A-11029
RRID:AB_138404
Goat anti-mouse IgG, 1:500)
antibody anti-Frataxin Santa Cruz biotechnology sc-25820
RRID:AB_2110677
Rabbit, 1:200
antibody anti-Akt Cell Signaling Technology 4691
RRID:AB_915783
Rabbit, 1:500
antibody anti-Caspase 8 Cell Signaling Technology 8592S
RRID:AB_10891784
Rabbit, 1:200
antibody Anti-b-Actin Sigma-Aldrich A1978
RRID:AB_476692
Mouse, 1:1000
antibody Anti-4-Hydroxynonenal Abcam ab46545
RRID:AB_722490
Rabbit, 1:3000
antibody Anti-4-Nitrotyrosine Abcam ab61392
RRID:AB_942087
Mouse, 1:3000
antibody Anti-phospho-PDK1 Cell Signaling Technology 3438S
RRID:AB_2161134
Rabbit, 1:1000
antibody Goat-anti-rabbit
HRP-conjugated
secondary antibody
ThermoFisher Scientific 31460
RRID:AB_228341
1:5000
antibody Goat-anti-mouse
HRP-conjugated
secondary antibody
ThermoFisher Scientific 32230
RRID:AB_1965958
1:5000
software, algorithm ImageJ https://imagej.nih.gov/ij/ RRID:SCR_003070
Continued on next page
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Continued
Reagent type (species)
or resource Designation Source or reference Identifiers Additional information
software, algorithm BLASTN https://blast.ncbi.nlm.nih.go RRID:SCR_001598
software, algorithm TopScan http://cleversysinc.com/?csi_
products=topscan-lite
RRID:SCR_014494
software, algorithm ImageScope http://www.aperio.com/ RRID:SCR_014311
software, algorithm CellProfiler Analyst http://cellprofiler.org RRID:SCR_010649
software, algorithm LIMMA http://bioinf.wehi.edu.au/limma/ RRID:SCR_010943
software, algorithm WGCNA http://www.genetics.ucla.edu/labs/
horvath/CoexpressionNetwork/
RRID:SCR_003302 Weighted Gene Co-expression
Network Analysis
software, algorithm DAVID tools http://david.abcc.ncifcrf.gov/ RRID:SCR_003033 Database for Annotation
Visualization and
Integrated Discovery
software, algorithm PubMatrix http://pubmatrix.grc.nia.nih.gov/ RRID:SCR_008236
software, algorithm AccessPoint http://freelandsystems.com/
accesspoint-suite/accesspoint/
RRID:SCR_015792
software, algorithm NOTOCORD-hem http://www.notocord.com/
software/notocord_hem
RRID:SCR_015793
In vitro frataxin knockdown
Six different shRNA sequences against the frataxin mRNA (Figure 1—figure supplement 1) were
cloned into the exchange vector (proprietary material obtained from TaconicArtemis GmbH) as
described in detail previously (Seibler et al., 2007). To increase confidence in our selected shRNA
sequence, we performed independent experiments utilizing six different shRNA sequence targeting
Fxn. We measured Fxn mRNA and protein levels in vitro after over-expression of these shRNA
sequences. N2A cells (ATCC CCL-131; RRID:CVCL_0470) were transduced with exchange vectors
containing the shRNA against frataxin using Fugene 6 (Promega, Madison, WI). After 24 hr, cells
were replated in media containing neomycin and were validated for efficient frataxin knockdown by
RT-PCR and Western blotting. All six shRNA sequence displayed significant Fxn knockdown, sug-
gesting the possibility of limited off-target effects, since multiple shRNAs targeting the same gene
(Fxn) produce comparable gene silencing efficacy.
We selected the most efficient shRNA (GGATGGCGTGCTCACCATTAA) for validation and gener-
ating the transgenic animal. To examine potential off-target effects more directly, we determined
the shRNA specificity by measuring global changes in gene expression pattern following the induc-
tion of shRNA expression targeting Fxn in our in vivo model. First, we screened and identified poten-
tial putative targets of the shRNA sequence (GGATGGCGTGCTCACCATTAA) across the entire
mouse genome utilizing the BLASTN program (RRID:SCR_001598). This identified 20 unique genes
as potential targets in the mouse genome, which included Fxn gene as top hit, with all 21 base pairs
matching as expected (Figure 1—figure supplement 2). The remaining potential targets had only
16 to 13 base pair matches. Next, we examined the gene expression levels for each potential target
gene present in our microarray data after induction of the shRNA. Fxn was the earliest and most
consistent gene showing significant down-regulation. We did not observe any changes in the RNA
levels of other potential targets at any stage in our gene expression analysis (Figure 1—figure sup-
plement 2), strong evidence against significant off-target effects.
Mouse LW-4 (129SvEv) embryonic stem cells were cultured and the rosa26 targeting vector (from
TaconicArtemis GmbH) were electroporated according to protocol described before (Seibler et al.,
2005). The exchange vector containing validated and selected shRNA sequence (GGATGGCGTGC
TCACCATTAA) against the Fxn mRNA were electroporated to obtain positive ES cells containing
shRNA expression cassette integrated into the ROSA26 locus. Correctly targeted embryonic stem
cell clones were utilized to generate frataxin knockdown mice (see below).
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Transgenic mouse generation
Transgenic mice were generated at UCLA Transgenic Core facility using proprietary materials
obtained from TaconicArtemis GmbH (Ko¨ln, Germany). In brief, mouse LW-4 (129SvEv) embryonic
stem cells with the recombinase-mediated cassette exchange (RMCE) acceptor site on chromosome
6 were used for targeting insertion of distinct Tet-On frataxin shRNA expression cassettes into the
ROSA26 locus (Seibler et al., 2007) as depicted in Figure 1. Correctly targeted embryonic stem cell
clones were identified by Southern DNA blot analysis and tested for frataxin mRNA knockdown at
the embryonic stem cell stage (not shown). One embryonic stem cell clone that gave acceptable
mRNA knockdown was microinjected into C57BL/6J blastocysts from which chimeric mice were
derived. These frataxin knockdown mice (FRDAkd) were backcrossed six generations into the
C57BL/6 mouse background (RRID:IMSR_JAX:000664).
Genotyping
Mouse tail biopsies were collected and DNA was extracted in boiling buffer (25 mM sodium hydrox-
ide, 0.2 mM EDTA) at 98˚C for 60 min. Extracted DNA was neutralized in Tris/HCl buffer (pH5.5) and
PCR was performed under the following conditions with BioMix Red (Bioline). Four primers were
used in the reaction: 5’-CCATGGAATTCGAACGCTGACGTC-3’, 5’-TATGGGCTATGAACTAA
TGACCC-3’, to amplify shRNA; 5’-GAGACTCTGGCTACTCATCC-3’, 5’- CCTTCAGCAAGAGC
TGGGGAC-3’, as genomic control. The cycling conditions for PCR amplification were: 95˚C for 5
min; 95˚C for 30 s, 60˚C for 30 s, 72˚C for 1 min, (35 cycles); 72˚C for 10 min. PCR products were
analyzed by gel electrophoresis using 1.5% agarose and visualized by Biospectrum imaging system
(UVP).
Animal and study design
Experiments were approved by the Animal Research Committee (ARC) of University of California,
Los Angeles and were in accordance with ARC regulation. Extensive neurological and neuropsycho-
logical tests (body weight, poorly groomed fur, bald patches in the coat, absence of whiskers, wild-
running, excessive grooming, freezing, hunched body posture when walking, response to object
[cotton-tip swab test], visual cliff behavior analysis) were performed to ensure all animals included in
the studies were healthy. Age and sex were matched between wild type (Wt) and transgenic (Tg)
groups to eliminate study bias. The average age of the animals at the start of experiments was 3–4
months. Three different study cohorts were implemented: behavior, pathology and gene expression.
Animals were randomly assigned to different experimental groups with in these three different study
cohorts before the start of experiments. Due to high mortality rate of FRDAkd animals, we doubled
the Tg + animal number (a sample size of 30 animals per Tg + treatment group for behavioral analy-
ses (60 total)) in order to have sufficient power for statistical analyses. All the group size for our
experiments were determined by statistical power analysis. The values utilized were: the power = 0.9,
alpha = 0.05, Coefficient of determination = 0.5, effect size = 0.70. Effect size and power calcula-
tions were based on our pilot experiments.
In vivo frataxin knockdown
Animals were divided into the following groups: Wt treated with doxycycline (Dox) (Wt +), Wt with-
out Dox (Wt -), Tg treated with Dox (Tg +), Tg without Dox (Tg -), Tg Dox rescue (Tg ±). First, we
examined the Tg + mice for frataxin knockdown utilizing higher dose of dox (4 and 6 mg/ml), we
observed mortality as early as two weeks and a 100% mortality rate by 5 to 6 weeks (not shown). To
avoid early mortality and to have slow and steady state of disease progression we followed 2 mg/ml
in drinking water coupled with intraperitoneal injection of dox (5 or 10 mg/kg) twice per week. Doxy-
cycline (2 mg/mL) was added to the drinking water of all treatment animals which was changed
weekly. In addition, animals were injected intraperitoneally (IP) with Dox (5 mg/kg body weight)
twice a week for 10 weeks followed by 10 mg Dox/kg body weight twice a week for 2 weeks. Ani-
mals in Tg Dox rescue (Tg ±) group were given untreated water and not injected with Dox after
week 12. All animals were weighed weekly.
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Behavior cohort
Animal information
A total of 108 animals (Wt n = 32, Tg n = 76) were included in this study with equal numbers of male
and female animals. For all tests, investigators were blinded to genotype and treatment. For all
behavioral tests, the variance between all the groups for that specific behavioral test were observed
to be initially not statistically significant.
Accelerating rotarod
To measure motor function, rotarod analysis was performed weekly at the start of Dox treatment
using an accelerating rotorod (ROTOMEX-5, Columbus Instruments, Columbus, OH). Mice were
assessed for 36 weeks. Briefly, after habituation, a mouse was placed on the rotarod rotating at 5
rpm for one min and then the rotorod was accelerated at 0.09 rpm/sec2. The latency to fall from a
rotating rod after acceleration was recorded. Each mouse was subjected to three test trials within
the same day with a 15 min inter-trial interval. The average latency normalized by the mouse body
weight in the test week was used for data analysis.
Grip strength test
The grip strength was measured at week 0, 12 and 24 weeks using a digital force gauge (Chatillon
Force Measurement Systems, AMETEK TCI Division, Largo, FL). Briefly, the mouse was allowed to
grasp the steel wired grid attached to the force gauge with only forepaws. The mouse was then
pulled back from the gauge. The force applied to the grip immediately before release of the grip is
recorded as the ‘peak tension’ and is a measurement of forepaw strength. The same measurement
was repeated with the mouse grasping the grid with all paws for whole grip strength. Each mouse
was subjected to three forepaw and whole strength measurements. The hindpaw grip strength was
calculated as the average whole grip strength minus average forepaw strength. The value of hind-
paw grip strength normalized by the mouse body weight in the test week was used for data analysis
(Crawley, 2007).
Gait analyses
Gait analysis was performed at week 0, 12 and 24 weeks by allowing the animals to walk through a
50-cm-long, 10-cm-wide runway that was lined with blank index cards. After a period of habituation
(walking through the runway three times), hind and fore paws was coated with nontoxic red and pur-
ple paint respectively and the mouse was allowed to walk through the runway again. Footprints
were captured on the index cards. The index cards were scanned and the images were measured in
image J (RRID:SCR_003070) for calculating the stride length and other parameters as per
(Carter et al., 2001).
Open field analyses
Open field activity monitoring system was used to assess the level of spontaneous locomotion and
behavioral activity. Open field testing was performed at week 0, 12 and 24 weeks in an open field
Plexiglas chamber with a video monitoring system that records any movement of mouse within the
chamber. Mice were placed in the chambers for 5 min to acclimate. The recording system was
turned on without disturbing the animals in the testing chambers. TopScan software (RRID:SCR_
014494) connected to the chamber was used to track the behavior of the animal during the testing.
Each mouse placed in different quadrants of open field chambers was recorded for 20 min. After the
end of the recording period the mouse was returned to their respective home cages. Locomotor
activity of the mice was analyzed by TopScan (CleverSys; RRID:SCR_014494) software.
Pathology cohort
Animal information
A total of 57 animals (Wt n = 21 (10 females, 11 males), Tg n = 36 (20 females, 16 males)) were
euthanized in the study. Animals were deeply anesthetized with sodium pentobarbital (40 mg/kg
body weight) and perfused intracardially with 20 mL PBS (5 mL/min) followed by 20 mL freshly made
4% paraformaldehyde (5 mL/min). Tissue from liver, lung, spleen, pancreas, kidney, heart, eye
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(retina), brain, muscle, spinal cord, dorsal root ganglion (DRG) and sciatic nerve was dissected and
collected immediately after perfusion. Collected tissue was immersed in 4% paraformaldehyde over-
night at 4˚C and then transferred and kept in 40% sucrose at 4˚C until embedded with O.C.T. Tissue
cryosections (5 mM) were collected with a cryostat for staining.
Staining
H&E staining was performed in the Translational Pathology Core Laboratory at UCLA using methods
described briefly below. After equilibration, the tissue section was stained with Harris Modified
Hematoxylin for 10 min, then in Eosin Y for 10 min. Gomori’s iron staining and Masson’s trichrome
staining were performed in Histopathology lab in UCLA, the procedure is described briefly as below.
Gomori’s iron staining: the tissue section was immersed for 20 min in equal parts of 20% hydro-
chloric acid and 10% potassium ferrocyanide, washed thoroughly in distilled water. After counter-
staining with Nuclear Fast Red (0.1% Kernechtrot in 5% aluminum sulfate), the slides were
dehydrated through gradual ethyl alcohol solutions and mounted for imagining. Masson’s trichrome
staining: the tissue section was fixed in Bouin’s fixative (75 mL picric acid saturated aqueous solution,
25 mL of 40% formaldehyde, 5 mL glacial acetic acid) for 60 min at 60˚C, stained with Weigert iron
hematoxylin (0.5% hematoxylin, 47.5% alcohol, 0.58% ferric chloride, 0.5% hydrochloric acid) for 10
min, Biebrich scarlet-acid fuchsin (0.9% Biebrich scarlet, 0.1% acid fuchsin, 1% glacial acetic acid) for
10 min, immersed in phosphomolybdic-phosphotungstic solution (2.5% phosphomolybdic acid, 2.5%
phosphotungstic acid) for 7 min, stained with aniline blue solution (2.5% aniline blue, 2% acetic acid)
for 7 min, dehydrate and mounted for imagining. Immunofluorescence staining was performed as
followed: cryosections were equilibrated with TBS (20 mM Tris pH7.5, 150 mM NaCl) and permeabi-
lized in TBST (TBS with 0.2% TritonX-100). Tissue sections were incubated with primary antibody in
TBST with 4% normal goat serum (Jackson Immuno Research) (4˚C, overnight), followed by incuba-
tion with secondary antibody in TBST with 4% normal goat serum (room temperature, 2 hr) the next
day. The tissue section was mounted with ProLong Gold with DAPI (ThermoFisher Scientific) and
stored in the dark. The following antibodies were used: anti-ferroportin-1 (LifeSpan BioSciences, LS-
B1836, rabbit, 1:200; RRID:AB_2254938), anti-ferritin (Abcam, ab69090, rabbit, 1:500; RRID:AB_
1523609), anti-LC3 (Abgent, AM1800a, mouse, 1:200; RRID:AB_2137696), anti-NeuN (EMD Milli-
pore, ABN91, chicken, 1:500; RRID:AB_11205760), anti-NeuN (EMD Millipore, ABN78, rabbit, 1:500;
RRID:AB_10807945). Secondary antibodies conjugated with Alexa Fluor (ThermoFisher Scientific,
1:500) were used as indicated: Alexa Fluor 488 (goat anti-Rabbit IgG, A-11008; RRID:AB_143165),
Alexa Fluor 594 (goat anti-chicken IgG, A-11039; RRID:AB_142924), and Alexa Fluor 488 (goat anti-
mouse IgG, A-11029; RRID:AB_138404). DNA strand breaks were determined by TUNEL assay
(Roche). Briefly, sections were equilibrated with PBS, permeabilized in 0.1% Triton X-100 in 0.1%
sodium citrate (on ice, 2 min) and incubated with TUNEL reaction mixture in a humidified atmo-
sphere (37˚C, 60 min). Sections were mounted with ProLong Gold with DAPI and stored in the dark.
Imaging and quantification
Slides stained for hematoxylin-eosin, iron, and trichrome were scanned (20 x magnification) by
Aperio ScanScope with Aperio ImageScope Software (Leica; RRID:SCR_014311). Immunofluores-
cence staining and TUNEL staining were imaged with LSM780 confocal microscope system (Zeiss).
Images were quantified by CellProfiler (RRID:SCR_010649). For Purkinje cell quantification, the H
and E images were scanned, visualized and exported by ImageScope (Leica; RRID:SCR_014311) sys-
tem. Exported images were utilized to count the Purkinje cells manually using NIH ImageJ software
(RRID:SCR_003070). Counting was conducted by investigators who were blinded to genotype and
treatment.
Electron microscopy analyses
A total of 29 animals (Wt n = 9 (four females, five males), Tg n = 20 (9 females, 11 males)) were used
in the study. Mice were perfused transcardially with 2.5% glutaraldehyde, 2% paraformaldehyde in
0.1M phosphate buffer, 0.9% sodium chloride (PBS). Pieces of heart, lumbar spinal cord, dorsal root
ganglia, muscle, and eye were dissected, postfixed for 2 hr at room temperature in the same fixa-
tive, and stored at 4˚C until processing. Tissues were washed with PBS, postfixed in 1% OsO4 in PBS
for 1 hr, dehydrated in a graded series of ethanol, treated with propylene oxide and infiltrated with
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Eponate 12 (Ted Pella) overnight. Tissues were embedded in fresh Eponate, and polymerized at
60˚C for 48 hr. Approximately 60–70 nm thick sections were cut on a RMC Powertome ultramicro-
tome and picked up on formvar coated copper grids. The sections were stained with uranyl acetate
and Reynolds lead citrate and examined on a JEOL 100CX electron microscope at 60 kV. Images
were collected on type 4489 EM film and the negatives scanned to create digital files. These high
quality digital images were utilized to quantify the number of condensed mitochondria. Condensed
mitochondria, vesicles with condensed mitochondria, and vesicles alone were manually counted with
NIH ImageJ software (RRID:SCR_003070). Animal genotype and treatment information was blinded
to the person who conducted the evaluation.
Gene expression cohort
Sample collection
A total of 80 animals (Wt n = 24 (12 females and 12 males), Tg n = 56 (31 females and 25 males))
were sacrificed and tissue was collected in this study. Animals were sacrificed at week 0, 3, 8, 12, 16,
20, and plus 4 and 8 weeks post dox treatment (rescue). Mice were sacrificed by cervical dislocation
and tissue from liver, lung, spleen, pancreas, kidney, heart, eye (retina), brain, muscle, spinal cord,
dorsal root ganglion (DRG) and sciatic nerve was dissected and rinsed in cold PBS quickly (3X) to
remove blood. Tissue samples were transferred immediately into 2 mL RNase-free tubes and
immersed into liquid nitrogen. The collected tissue was stored at  80˚C immediately.
RNA extraction
Heart, cerebellum and DRG neuron samples from week 0, 3, 12, 16, 20 and 4, 8 weeks post dox
treatment (rescue), each with four biological replicates, were used for expression profiling. Samples
were randomized prior to RNA extraction to eliminate extraction batch effect. Total RNA was
extracted using the miRNeasy mini kit (Qiagen) according to manufacturer’s protocol and including
an on-column DNase digest (RNase free DNAse set; Qiagen). RNA samples were immediately ali-
quoted and stored at  80˚C. RNA concentration and integrity were later determined using a Nano-
drop Spectrophotometer (ThermoFisher Scientific) and TapeStation 2200 (Agilent Technologies),
respectively.
Transcriptome profiling by microarray
One hundred nanograms of RNA from heart and cerebellum tissue was amplified using the Illumina
TotalPrep-96 RNA Amplification kit (ThermoFisher Scientific) and profiled by Illumina mouse Ref 8
v2.0 expression array chips. For DRG samples 16.5 ng of RNA was amplified using the Ovation
PicoSL WTA System V2 kit (NuGEN). Only RNA with RIN greater than 7.0 was included for the study.
A total of 64 RNA samples for each tissue (n = 192 arrays) were included and samples were random-
ized before RNA amplification to eliminate microarray chip batch effect. Raw data was log trans-
formed and checked for outliers. Inter-array Pearson correlation and clustering based on variance
were used as quality-control measures. Quantile normalization was used and contrast analysis of dif-
ferential expression was performed by using the LIMMA package (Smyth, 2005; RRID:SCR_010943).
Briefly, a linear model was fitted across the dataset, contrasts of interest were extracted, and differ-
entially expressed genes for each contrast were selected using an empirical Bayes test statistic
(Smyth, 2005).
Construction of co-expression networks
A weighted signed gene co-expression network was constructed for each tissue dataset to identify
groups of genes (modules) associated with temporal pattern of expression changes due to frataxin
knockdown and rescue following a previously described algorithm (Zhang and Horvath, 2005;
Oldham et al., 2006; RRID:SCR_003302). Briefly, we first computed the Pearson correlation
between each pair of selected genes yielding a similarity (correlation) matrix. Next, the adjacency
matrix was calculated by raising the absolute values of the correlation matrix to a power (b) as
described previously (Zhang and Horvath, 2005). The parameter b was chosen by using the scale-
free topology criterion (Zhang and Horvath, 2005), such that the resulting network connectivity dis-
tribution best approximated scale-free topology. The adjacency matrix was then used to define a
measure of node dissimilarity, based on the topological overlap matrix, a biologically meaningful
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measure of node similarity (Zhang and Horvath, 2005). Next, the probe sets were hierarchically
clustered using the distance measure and modules were determined by choosing a height cutoff for
the resulting dendrogram by using a dynamic tree-cutting algorithm (Zhang and Horvath, 2005).
Consensus module analyses
Consensus modules are defined as sets of highly connected nodes that can be found in multiple net-
works generated from different datasets (tissues) (Chandran et al., 2016). Consensus modules were
identified using a suitable consensus dissimilarity that were used as input to a clustering procedure,
analogous to the procedure for identifying modules in individual sets as described elsewhere
(Langfelder and Horvath, 2007). Utilizing consensus network analysis, we identified modules shared
across different tissue data sets after frataxin knockdown and calculated the first principal compo-
nent of gene expression in each module (module eigengene). Next, we correlated the module eigen-
genes with time after frataxin knockdown to select modules for functional validation.
Gene ontology, pathway and PubMed analyses
Gene ontology and pathway enrichment analysis was performed using the DAVID platform (DAVID,
https://david.ncifcrf.gov/ (Huang et al., 2008); RRID:SCR_003033). A list of differentially regulated
transcripts for a given modules were utilized for enrichment analyses. All included terms exhibited
significant Benjamini corrected P-values for enrichment and generally contained greater than five
members per category. We used PubMatrix (Becker et al., 2003); RRID:SCR_008236) to examine
each differentially expressed gene’s association with the observed phenotypes of FRDAkd mice in
the published literature by testing association with the key-words: ataxia, cardiac fibrosis, early mor-
tality, enlarged mitochondria, excess iron overload, motor deficits, muscular strength, myelin sheath,
neuronal degeneration, sarcomeres, ventricular wall thickness, and weight loss in the PubMed data-
base for every gene.
Data availability
Datasets generated and analyzed in this study are available at Gene Expression Omnibus. Accession
number: GSE98790. R codes utilized for data analyses are available in the following link: https://
github.com/dhglab/FxnMice
Quantitative real-time PCR
RT-PCR was utilized to measure the mRNA expression levels of frataxin in order to identify and vali-
date potent shRNA sequence against frataxin gene. The procedure is briefly described below: 1.5
mg total RNA, together with 1.5 mL random primers (ThermoFisher Scientific, catalog# 48190–011),
1.5 mL 10 mM dNTP (ThermoFisher Scientific, catalog# 58875) and RNase-free water up to 19.5 mL,
was incubated at 65˚C for 5 min, then on ice for 2 min; 6 mL first strand buffer, 1.5 mL 0.1 M DTT, 1.5
mL RNaseOUT (ThermoFisher Scientific, catalog# 100000840) and 1.5 mL SuperScript III (Thermo-
Fisher Scientific, catalog# 56575) were added to the mixture and incubated for 5 min at 25˚C, fol-
lowed by 60 min at 50˚C, and 15 min at 70˚C. The resulted cDNA was diluted 1:10 and 3 mL was
mixed with 5 mL SensiFast SYBR No-ROX reagent (Bioline, catalog# BIO-98020), 0.6 mL primer set
(forward and reverse, 10 mM) and 1.4 mL nuclease free water for real-time PCR. Each reaction was
repeated three times on LightCycler 480 II (Roche, catalog# 05015243001). To check Mef2 activity,
the regulation of its target downstream genes were determined by qPCR on cerebellum and heart
RNA samples at week 20, utilizing previously validated primers (Chen et al., 2016b) and the follow-
ing thermocycling conditions: 95˚C 5 min; 95˚C 10 s, 60˚C 10 s, 72˚C 10 s, repeat 45 cycles; 95˚C 5 s,
65˚C 1 min, 97˚C 5 min.
Western blotting
Prior to samples being analyzed by Western blotting, protein concentration was estimated by Brad-
ford assay (Bio-Rad). Proteins were separated by SDS-PAGE and transferred onto PVDF membranes.
The membranes were incubated with primary and secondary antibodies for protein detection. The
target bands were detected with antibodies: anti-Frataxin (Santa Cruz Biotechnology, sc-25820, rab-
bit, 1:200; RRID:AB_2110677), anti-Akt (Cell Signaling Technology, #4691, rabbit, 1:500; RRID:AB_
915783), anti-b-Actin (Sigma, #A1978, mouse, 1:1000; RRID:AB_476692), anti-Caspase 8 (rabbit
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monoclonal, Cell Signaling Technology, #8592S, rabbit, 1:200; RRID:AB_10891784), anti-LC3
(Abgent, # AM1800a, mouse, 1:200; RRID:AB_2137696) and goat-anti-rabbit or goat-anti-mouse
HRP-conjugated secondary antibodies (ThermoFisher Scientific, #31460; RRID:AB_228341, and
#32230; RRID:AB_1965958, respectively,1:5000).
To determinate the ROS level, three different ROS related protein modifications were measured
in three different tissue types (brain, muscle and liver) at two different time points (wk12 an wk20).
Briefly, anti-4-Hydroxynonenal (Abcam, ab46545, rabbit, 1:3000) antibody was used to detect alde-
hydic products of lipid peroxidation; anti-3-Nitrotyrosine (Abcam, ab61392, mouse, 1:3000) antibody
was used to detect protein tyrosine nitration, an important component of nitric oxide signaling; and
OxyBlot Protein Oxidation Detection Kit (Millipore, Cat#S7150) was used to detect the carbonyl
groups of protein side, a product of protein oxidative modification. To determinate the phosphoryla-
tion of PDK1, anti-pPDK1 (Cell Signaling Technology, #3438, rabbit, 1:1000), and goat-anti-rabbit
HRP-conjugated secondary antibody (ThermoFisher Scientifc, #31460, 1:5000) were used. Image J
was used for band quantification.
Enzyme activity assay
Proteins from heart tissue for all genotypes at week 20 was extracted in Tris buffer (50 mM Tris-HCl
pH 7.4). Around 80 mg of tissue was homogenized with 100 mL Tris buffer, and centrifuged at 800 g
for 10 min at 4˚C. The supernatant was transferred to a clean tube and stored at  80˚C freezer
immediately for later use. Protein concentration was estimated by Bradford assay. Total of 5 mg of
protein was used to determine aconitase activity by aconitase assay kit (Cayman Chemical, catalog#
705502). The absorbance of the reaction mixture at 340 nm was measured every minute for 60 min
at 37˚C, by Synergy-2 (BioTek) plate reader. The linear phase was used to calculate the enzyme activ-
ity. 5 mg of protein was used to measure citrate synthase activity by citrate synthase assay kit (Sigma,
catalog# CS0720). The absorbance of the reaction mixture at 412 nm was measured by Synergy-2
plate reader every 31 s for 30 min at room temperature. The linear phase was used to calculate the
enzyme activity. Aconitase activity in each sample was normalized to the citrate synthase activity
from the same sample for comparison.
Echocardiography
Echocardiography was performed with a Siemens Acuson Sequoia C256 instrument (Siemens Medi-
cal Solutions, Mountain View, California). The mice were sedated with isoflurane vaporized in oxygen
(Summit Anesthesia Solutions, Bend Oregon). Left ventricular dimensions (EDD, end diastolic dimen-
sion; ESD, end systolic dimension; PWT, posterior wall thickness; VST, ventricular septal thickness)
were obtained from 2D guided M-mode and was analyzed using AccessPoint software (Freeland Sys-
tem LLC, Santa Fe, New Mexico; RRID:SCR_015792) during systole and diastole. Left ventricular
mass was calculated as described previously (Tanaka et al., 1996). Heart rate, aortic ejection time,
aortic velocity and mitral inflow E and A wave amplitudes were determined from Doppler flow
images. Indices of contractility such as left ventricular fractional shortening (LVFS), velocity of circum-
ferential fiber shortening (VCF) and ejection fraction (EF) was obtained from the images. During the
procedure, heart rates were maintained at physiological levels by monitoring their electrocardio-
grams (ECG).
Surface ECG
Electrocardiogram (ECG) were obtained in all the mice under Isoflurane anesthesia by inserting two
Pt needle electrodes (Grass Technologies, West Warwick, RI) under the skin in the lead II configura-
tion as described previously (Nakashima et al., 2014). The mice were studied between 10 and 30
min to elucidate any rhythm alteration. The ECG data were amplified (Grass Technologies) and then
digitized with HEM V4.2 software (Notocord Systems, Croissy sur Seine, France; RRID:SCR_015793).
Measurements of HR, PR, RR, QRS, QT intervals were obtained for comparison and statistical analy-
sis among all the mice groups.
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accession: GSE98790.
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